References with PepMix™ Peptide Pools - Infectious Diseases
2024
2024
- COVID-19 vaccination induces distinct T-cell responses in pediatric solid organ transplant recipients and immunocompetent children
Roznik et al., Vaccines (2024)
Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (Spike B.1.1.529 / BA.4 & BA.5 / Omicron) - Innate Responses to the Former COVID-19 Vaccine Candidate CVnCoV and Their Relation to Reactogenicity and Adaptive Immunogenicity
Wolz et al., Vaccines (2024)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) - The Micro-Immunotherapy Medicine 2LPAPI® Displays Immune-Modulatory Effects in a Model of Human Papillomavirus Type-16 L1-Protein Capsid-Treated Human Peripheral Blood Mononuclear Cells and Antiproliferative Effects in a Model of Cervical Cancer Cells
Jacques et al., Cancers (2024)
Product used: PepMix HPV16 (L1) - From Vaccination to Infection: Mechanistic Studies of Immune Responses to SARS-COV-2
Lenart, Dissertation (2024)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) - Immunogenicity and efficacy of VLA2001 vaccine against SARS-CoV-2 infection in male cynomolgus macaques
Galhaut et al., Communications Medicine (2024) - PMID: 38570605
Products used: PepMix SARS-CoV-2 (S-RBD), SARS-CoV-2 (NCAP) - Evaluation of T Cell Response to SARS-CoV-2 in Kidney Transplant Recipients Receiving Monoclonal Antibody Prophylaxis and the Utility of a Bivalent mRNA Vaccine Booster Dose
Bertrand et al., Microorganisms (2024)
Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), SARS-CoV-2 (NCAP), SARS-CoV-2 (NS7A), SARS-CoV-2 (VEMP), SARS-CoV-2 (VME1), SARS-CoV-2 (Nsp3), CEFX Ultra SuperStim Pool - Carrier-free mRNA vaccine induces robust immunity against SARS-CoV-2 in mice and non-human primates without systemic reactogenicity
Abbasi et al., Molecular Therapy (2024)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) - T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination
Verstegen et al., Multiple Sclerosis (2024) - PMID: 38548324
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2) - Children treated against lymphoid malignancies display diminished IFN-gamma producing T cells after polyclonal and Varicella zoster virus peptide activation
Tiselius et al., Research Square (2024)
Product used: PepMix VZV (gE) and VZV (IE63) - LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study
Musher et al., The Lancet Oncology (2024) - PMID: 38547893
Product used: PepMix Human Adenovirus 26 (Hexon Protein) and Human Adenovirus 26 (Penton Protein) - Comparable CD8+ T‐cell responses to SARS‐CoV‐2 vaccination in single‐cell transcriptomics of recently allogeneic transplanted patients and healthy individuals
Tranter et al., Journal of Medical Virology (2024)
Product used: CEFX Ultra SuperStim Pool, PepMix SARS-CoV-2 (NCAP), SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), SARS-CoV-2 AP3A (ORF3a), SARS-CoV-2 NS7A, SARS-CoV-2 NS8, Pan‐SARS-CoV-2 Select, and custom PepMix - Generation of CRISPR-Cas9-edited Tacrolimus-resistant SARS-CoV-2-specific T-cells for adoptive cell therapy in transplant patients
Peter, Dissertation (2024)
Products used: PepMix CMVA (pp65), SARS-CoV-2 peptide pools (NCAP, Spike S1, Spike S2, VEMP, VME1, AP3a, NS6, NS7a, NS7b, NS8, ORF9b, ORF10, Y14) - LVS ΔcapB-vectored multiantigenic melioidosis vaccines protect against lethal respiratory Burkholderia pseudomallei challenge in highly sensitive BALB/c mice
Tullius et al., Vaccines (2024)
Product used: PepMix BKV (small T antigen) - Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine
Harris et al., Vaccines (2024) - Development and Characterization of a Novel DC-Targeting Universal Influenza Vaccine
Olukitibi et al., Dissertation (2024)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1) - A vaccine targeting antigen-presenting cells through CD40 induces protective immunity against Nipah disease
Pastor et al., Cell Reports Medicine (2024) - PMID: 38471503
Products used: PepMix Nipah Virus (Nucleoprotein N), Nipah virus (Glycoprotein G), Nipah Virus (Fusion Glycoprotein F0), custom PepMix Nipah ECD - Single MVA-SARS-2-ST/N Vaccination Rapidly Protects K18-hACE2 Mice against a Lethal SARS-CoV-2 Challenge Infection
Clever et al., Viruses (2024)
Product used: PepMix SARS-CoV-2 (NCAP), SARS-CoV-2 Antigen Peptide NCAP (LALLLLDRL), Antigen Peptide IFN-gR H-2 Kb (TSYKFESV) - NFκB and NLRP3/NLRC4 inflammasomes regulate differentiation, activation and functional properties of monocytes in response to distinct SARS-CoV-2 proteins
Tsukalov et al., Nature Communications (2024) - PMID: 38453949
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1), SARS-CoV-2 (NCAP) - Comparable safety and non-inferior immunogenicity of the SARS-CoV-2 mRNA vaccine candidate PTX-COVID19-B and BNT162b2 in a phase 2 randomized, observer-blinded study
Reiter et al., Scientific Reports (2024) - PMID: 38438427
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) - Ad26.M.Env ZIKV vaccine protects pregnant rhesus macaques and fetuses against Zika virus infection
Martinot et al., Research Square (2024)
Product used: PepMix ZIKV (E) Ultra, ZIKV (M) Ultra - Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial.
Pant et al., Nature Medicine (2024) - PMID: 38195752
Product used: PepMix Pan-CMV Select, CMVA (pp65), SARS-CoV-2 (S-RBD) - Cognate Antigen Engagement induces HIV-1 Expression in CD4+ T cells from people in long-term Art
Moskovljevic et al., BioRxiv (2024)
Product used: PepMix™ HIV-1 (GAG) Ultra - Bivalent mRNA COVID vaccines elicit predominantly cross-reactive CD4+ T cell clonotypes
Sop et al., Cell Reports Medicine (2024) - PMID: 38423018
Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (Spike B.1.1.529 / BA.4 & BA.5 / Omicron) - Immune responses to SARS-CoV-2 mRNA vaccination in people with idiopathic CD4 lymphopenia
Rocco et al., Translational and Clinical Immunology (2024) - PMID: 38344971
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) - Multivalent cytomegalovirus glycoprotein B nucleoside modified mRNA vaccines did not demonstrate a greater antibody breadth
Wang et al., Vaccines (2024) - PMID: 38378950
Product used: custom PepStar, PepMix™ CMVA (UL55) - Applying valency-based immuno-selection to generate broadly cross-reactive antibodies against influenza hemagglutinins
Hinke et al., Nature Communications (2024) - PMID: 38346952
Products used: PepMix™ Influenza A (HA/Puerto Rico/8/1934 H1N1), PepMix™ Influenza A (HA /California (H1N1)) - Integrating Machine Learning-Enhanced Immunopeptidomics and SARS-CoV-2 PopulationScale Analyses Unveils Novel Antigenic Features for Next-Generation COVID-19 Vaccines
Caron et al., Research Square (2024)
Product used: PepMix™ HIV-1 (POL) Ultra - Vaccines targeting ESR1 activating mutations elicit anti-tumor immune responses and suppress estrogen signaling in therapy resistant ER+ breast cancer
Dailey et al., Human Vaccines & Immunotherapeutics (2024) - PMID: 38330990
Products used: Custom PepMix (ESR1), PepMix™ HIV-1 (GAG) Ultra - A Gamma-adapted subunit vaccine induces broadly neutralizing antibodies against SARS-CoV-2 variants and protects mice from infection
Coria et al., Nature Communications (2024) - PMID: 38307851
Products used: PepMix™ SARS-CoV-2 (S-RBD), PepMix™ SARS-CoV-2 (S-RBD P.1 / Gamma) - Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer
Debie et al., Clinical Cancer Research (2024) - PMID: 36341493
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2) - Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial
Pant et al., Nature Medicine (2024) - PMID: 38195752
Products used: PepMix™ SARS-CoV-2 (S-RBD),CEFSX Ultra SuperStim Pool, CEFT Pool, PepMix™ Pan-CMV Select, PepMix CMVA pp65, PepMix™ Pan-EBV Select, CEF Pool (standard) - MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike reveal differential immunogenicity in humans
Mayer et al., Vaccines (2024) - PMID: 38278816
Product used: CEF Pool (extended), PepMix™SARS-CoV-2 (Spike Glycoprotein) - Low pre-existing endemic human coronavirus (HCoV-NL63)-specific T cell frequencies are associated with impaired SARS-CoV-2-specific T cell responses in people living with HIV
Ng'uni et al., Frontiers in Immunology (2024)
Products used: PepMix™ SARS-CoV-2 (Spike B.1.617.2 / Delta), PepMix™ HCoV-NL63 (Spike Glycoprotein), PepMix™ SARS-CoV-2 (Spike B.1.351 / Beta) - T Cell Responses against Orthopoxviruses in HIV-Positive Patients
Stefanie et al., Vaccines (2024)
Product used: PepMix™ Pan-Poxviridae Select - Caveats of chimpanzee ChAdOx1 adenovirus-vectored vaccines to boost anti-SARS-CoV-2 protective immunity in mice
Cervantes-Torres et al., Applied Microbiology and Biotechnology (2024) - PMID: 38280035
Product used: PepMix™ SARS-CoV-2 (S-RBD B.1.617.2 / Delta) - Comparison of Omicron Breakthrough Infection Versus Monovalent SARS-CoV-2 Intramuscular Booster Reveals Differences in Mucosal and Systemic Humoral Immunity
Nantel et al., Mucosal Immunology (2024)
Products used: PepMix™SARS-CoV-2 (Spike P.1 / Gamma), PepMix™ SARS-CoV-2 (Spike B.1.351 / Beta), PepMix™ SARS-CoV-2 (Spike B.1.617.2 / Delta), PepMix™ SARS-CoV-2 (Spike B.1.1.7 / Alpha), PepMix™ SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron) - Expanded specific T cells to hypomutated regions of the SARS-CoV-2 using mRNA electroporated antigen presenting cells.
Ogando-Rivas et al., Methods and Clinical Development (2024)
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), PepMix™ SARS-CoV-2 (VME1), PepMix™ SARS-CoV-2 (VEMP), PepMix™SARS-CoV-2 (NCAP) - Enhanced detection of antigen-specific T cells by a multiplexed AIM assay
Lemieux et al., Cell Rep Methods (2024) - PMID: 38228152
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), PepMix™ HIV-1 (GAG) Ultra, PepMix™ HIV-1 (POL) Ultra, PepMix™ HIV-1 (ENV) Ultra, PepMix™ HIV-1 (NEF) Ultra, PepMix™ CMVA (pp65) - Three immunizations with Novavax’s protein vaccines increase antibody breadth and provide durable protection from SARSCoV-2
Lenart et al., Vaccines (2024) - PMID: 38245545
Products used: PepMix™SARS-CoV-2 (Spike Glycoprotein) - Identification of a spike-specific CD8+ T cell epitope following vaccination against the Middle East respiratory syndrome coronavirus in humans
Harrer et al., Journal of Infectious Diseases (2024) - PMID: 38195212
Products used: PepMix™ MERS-CoV (Spike Glycoprotein), CEF Pool (extended) - Surface-modified measles vaccines encoding oligomeric, prefusion-stabilized SARS-CoV-2 spike glycoproteins boost neutralizing antibody responses to Omicron and historical variants, independent of measles seropositivity
Muñoz-Alía et al., mBio (2024) - PMID: 38193729
Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) - CD3-downregulation identifies T-helper-cells with superior functionality and distinct metabolism in SARS-CoV2-vaccination- and recall-antigen-specific immunity
Sattler et al., JCI Insight (2024)
Products used: PepMix™ SARS-CoV-2 (Spike B.1.1.7 / Alpha), SARS-CoV-2 Antigen Peptide Spike Fusion (SFIEDLLFNKVTLAD) - Humoral and cellular immune responses after COVID-19 vaccination of lung transplant recipients and patients on the waiting list: a 6-month follow-up
Hoek et al., Frontiers in Immunology (2024)
Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) - Protective MVA-ST Vaccination Robustly Activates T Cells and Antibodies in an Aged-Hamster Model for COVID-19
Clever et al., Vaccines (2024)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) - Optimising a linear ‘Doggybone’ DNA vaccine for influenza virus through the incorporation of DNA targeting sequences and neuraminidase antigen
Cunliffe et al., Discovery Immunology (2024)'
Product used: PepMix Influenza A (Neuroamidase /California (H1N1) - A quest for universal anti-SARS-CoV-2 T cell assay: systematic review, meta-analysis, and experimental validation
Binayke et al., NPJ Vaccines (2024) - PMID: 38167915
Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), PepMix Pan-SARS-CoV-2 Select
2023
2023
- Hepatitis E Virus Epidemiology and Vaccine Response: Studies from Norway and Bangladesh
Øverbø, Dissertation (2023)
Product used: PepMix HEV (ORF2) - Ineffective control of Epstein-Barr-virus-induced autoimmunity increases the risk for multiple sclerosis
Vietzen et al., Cell (2023) - PMID: 38091993
Product used: PepMix™ Collection EBV - Evaluation of Luciferase and Prefusion-Stabilized F Protein From Respiratory Syncytial Virus mRNA/LNPs in Pre-Clinical Models Using Jet Delivery Compared to Needle and Syringe
Meyer et al., Vaccine (2023)
Product used: PepMix™ HRSVA (Fusion Glycoprotein F0) - The immunogenicity and the safety of the adjuvanted glycoprotein E (gE)-based recombinant vaccine against herpes zoster (RZV) in cancer patients during immunotherapy
Lasagna et al., Human Vaccines & Immunotherapeutics (2023) - PMID: 38037900
Products used: PepMix VZV (IE63), PepMix VZV (gE) - Interaction dynamics between innate and adaptive immune cells responding to SARSCoV-2 vaccination in non-human primates
Schramm et al., Nature Communications (2023) - PMID: 38042809
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) - Safety, immunogenicity and efcacy of an mRNA‑based COVID‑19 vaccine, GLB‑COV2‑043, in preclinical animal models
Lelis et al., Scientific Reports (2023) - PMID: 38040905 - Production, purification and immunogenicity of Gag virus-like particles carrying SARS-CoV-2 components
Gashti et al., Vaccine (2023) - PMID: 38042697
Product used: PepMix SARS-CoV-2 (NCAP) - Conjugation of HIV-1 envelope to hepatitis B surface antigen alters vaccine responses in rhesus macaques
Nettere et al., Vaccines (2023) - PMID: 38001122
Products used: PepMix HBV (Large envelope protein), PepMix HIV-1 (ENV) Ultra - Associations of myeloid cells with cellular and humoral responses following vaccinations in patients with neuroimmunological diseases
Wang et al., Nature Communications (2023) - PMID: 38007484
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) - Impaired Cellular and Antibody immunity after COVID-19 in Chronically Immunosuppressed Transplant Recipients
Ashokkumar et al., Journal of Surgery and Research (2023)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB2) - Immunotherapy of cytomegalovirus infection by low-dose adoptive transfer of antiviral CD8 T cells relies on substantial post-transfer expansion of central memory cells but not effector-memory cells
Holtappels et al., PLoS Pathogens (2023)
Product used: custom PepMix - Hydroxyurea interaction with α7 nicotinic acetylcholine receptor can underlie its therapeutic efficacy upon COVID-19
Lykhmus et al., Neuroimmunology (2023) - PMID: 38016403
Product used: custom PepMix - Concomitant administration of seasonal influenza and COVID-19 mRNA vaccines
Aydillo et al., Emerging Microbes & Infections (2023) - PMID: 38054302
Products used: PepMix Influenza A (HA/H1N1/Victoria/2019), Influenza A (HA/H3N2/Darwin/2021), custom PepMix Influenza B Nucleoprotein - A Phase I/II Clinical Trial of Intradermal, Controllable Self-Replicating Ribonucleic Acid Vaccine EXG-5003 against SARS-CoV-2
Koseki et al., Vaccines (2023)
Product used: PepMix SARS-CoV-2 (S-RBD) - Efectiveness ofVSV vectored SARS‑CoV‑2 spike when administered through intranasal, intramuscular or a combination of both
Beitari et al., Scientific Reports (2023) - PMID: 38049498
Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2) - Tiza–Titre increase and enhanced immunity through an adjuvanted, recombinant herpes zoster subunit vaccine in patients with liver cirrhosis and post-liver transplantation: a study protocol for a prospective cohort study
Vollmer-Raschdorf et al., BMJ Open (2023)
Product used: PepMix VZV (gE) - Caracterización del agotamiento de los linfocitos T en pacientes con síndrome Long COVID
Benéitez, Thesis (2023)
Products used: PepMix Influenza A (HA/California (H1N1)), custom PepMix Influenza (HA/Perth (H3N2)) - Cytomegalovirus-specific T cell immunity reconstitution following allogeneic hematopoietic stem cell transplantation: a pilot study
Wang et al., Research Square (2023)
Products used: PepMix CMVA (IE-1), PepMix CMVA (pp65) - Immunogenicity of a silica nanoparticle-based SARS-CoV-2 vaccine in mice
Barbey et al., European Journal of Pharmaceutics and Biopharmaceutics (2023) - PMID: 37774890
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2) - Impaired immune responses and prolonged viral replication in lung allograft recipients infected with SARS‑CoV‑2 in the early phase after transplantation
Glueck et al., Infection (2023) - PMID: 37922037
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) - Early humoral and cellular responses after bivalent SARS‐CoV‐2 mRNA‐1273.214 vaccination in long‐term care and retirement home residents in Ontario, Canada: An observational cohort study
Breznik et al., Journal of Medical Virology (2023) - PMID: 37822054
Product used: PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron) - Cytomegalovirus-Specific T Cells in Pediatric Liver Transplant Recipients
Getsuwan et al., Viruses (2023)
Products used: PepMix CMVA (IE-1), PepMix CMVA (pp65) - Humoral and Cellular Immunity Are Significantly Affected in Renal Transplant Recipients, Following Vaccination with BNT162b2
Fylaktou et al., Vaccines (2023)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) - Structural surfaceomics reveals an AML-specific conformation of integrin β2 as a CAR T cellular therapy target
Mandal et al., Nature Cancer (2023)
Products used: PepMix EBV (LMP1), PepMix EBV (EBNA1), PepMix EBV (LMP2), PepMix EBV (BZLF1), PepMix EBV (BRLF1), PepMix CMVA (pp65), PepMix CMVA (IE-1) - SARS-CoV-2 infection establishes a stable and age-independent CD8+ T cell response against a dominant nucleocapsid epitope using restricted T cell receptors
Choy et al., Nature Communications (2023) - PMID: 37872153
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1) - Revaccination of patients with systemic lupus erythematosus or rheumatoid arthritis without an initial COVID-19 vaccine response elicits seroconversion in half of the patients
Ammitzbøll et al., Clinical and Experimental Rheumatology (2023) - PMID: 37877429 - An interferon-integrated mucosal vaccine provides pan-sarbecovirus protection in small animal models
Yuen et al., Nature Communications (2023) - PMID: 37875475
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) - Dendritic Cell-Mediated Cross-Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS-CoV-2
Lázaro-Gorines et al., Advanced Science (2023)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) - Immunology of THymectomy And childhood CArdiac transplant (ITHACA): protocol for a UK-wide prospective observational cohort study to identify immunological risk factors of post-transplant lymphoproliferative disease (PTLD) in thymectomised children
Offor et al., BMJ Open (2023) - PMID: 37865406
Products used: custom PepMix - T regulatory lymphocytes specific for SARS-CoV-2 display increased functional plasticity
Esparcia-Pinedo et al., Clinical Immunology - PMID: 37827267
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), PepMix™ CMVA (pp65) - Immune Profile Determines Response to Vaccination against COVID-19 in Kidney Transplant Recipients
Stai et al., Vaccines (2023) - PMID: 37896986
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) - Cytokine profile of anti-spike CD4+T cells predicts humoral and CD8+T cell responses after anti-SARSCoV-2 mRNA vaccination
Tartour et al., Research Square (2023) - PMID
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2) - Pretransplant BKV-IgG serostatus and BKV-specific ELISPOT assays to predict BKV infection after kidney transplantation
Bae et al., Frontiers in Immunology (2023) - PMID: 37809095
Products used: PepMix BKV (capsid protein VP1), PepMix BKV (capsid protein VP2), PepMix BKV (capsid protein VP2, isoform VP3) - An RNA-Scaffold Protein Subunit Vaccine for Nasal Immunization
Lam et al., Vaccines (2023) - PMID: 37896953
Product used: PepMix SARS-CoV-2 (S-RBD) - Selection of cross-reactive T cells by commensal and food-derived yeasts drives cytotoxic TH1 cell responses in Crohn’s disease
Martini et al., Nature Medicine (2023) - PMID: 37749331
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) - Preexisting Enhancing Antibodies in Vaccinated Participants Accelerate Dengue Virus 1 Infection Following Live Virus Human Challenge
Lyke et al., Research Square (2023)
Product used: Custom PepMix - Enhanced Omicron subvariant cross-neutralization efficacy of a SARS-CoV-2 BA.4/5 mRNA vaccine encoding a noncleaved, nonfusogenic spike antigen
Oh et al., Research Square (2023)
Product used: PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.4 & BA.5 / Omicron) - Spontaneous HIV expression during suppressive ART is associated with the magnitude and function of HIVspecific CD4+ and CD8+ T cells
Dubé et al., Cell Hosts Microbe (2023) - PMID: 37708853
Products used: PepMix SARS-CoV-2 (Spike Glycoprotein) - Responses of patients with cancer to mRNA vaccines depend on the time interval between vaccination and last treatment
Donhauser et al., Journal for ImmunoTherapy of Cancer - PMID: 37730271
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) - Long-term humoral and cellular immunity after primary SARS-CoV-2 infection: A 20- month longitudinal study
Hvidt et al., Research Square (2023) - PMID: 37974069
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) - SARS-CoV-2 variants of concern elicit divergent early immune responses in hACE2 transgenic mice
Fricke et al., European Journal of Immunology (2023) - PMID: 37609807
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) - A cell-free antigen processing system informs HIV-1 epitope selection and vaccine design
Sengupta et al., Journal of Experimental Medicine (2023) - PMID: 37058141
Products used: PepMix HIV-1 (NEF) Ultra, HIV-1 (Con B gag motif) - Lymph node dendritic cells harbor inducible replication-competent HIV despite years of suppressive ART
Banga et al., Cell Host & Microbe (2023) - PMID: 37751747 - Ablative radiation alone in stage I lung cancer produces an adaptive systemic immune response: insights from a prospective study
Voong et al., Journal for ImmunoTherapy of Cancer (2023)
Products used: CEFX Ultra SuperStim Pool MHC-II Subset & PepMix™ HIV-1 (GAG) Ultra - Enhancing Anti-SARS-CoV-2 Neutralizing Immunity by Genetic Delivery of Enveloped Virus-like Particles Displaying SARS-CoV-2 Spikes
Yang et al., Vaccines (2023)
Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2) - Early Omicron infection is associated with increased reinfection risk in older adults in long-term care and retirement facilities
Breznik et al., The Lancet (2023)
Product used: PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron) - First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial
Thibaudin et al., Nature Medicine (2023) - PMID: 37563240
Products used: PepMix Human (NY-ESO-1) - Intradermal administration of DNA vaccine targeting Omicron SARS‑CoV‑2 via pyro‑drive jet injector provides the prolonged neutralizing antibody production via germinal center reaction
Hayashi et al., Scientific Reports (2023) - PMID: 37563266
Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron) - Lymph node targeted multi-epitope subunit vaccine promotes effective immunity to EBV in HLA-expressing mice
Dasari et al., Nature Communications (2023) - PMID: 37553346
Products used: PepMix EBV (GP350/GP340) - Safety and immunogenicity of a SARS-CoV-2 Gamma variant RBD-based protein adjuvanted vaccine used as booster in healthy adults
Pasquevich et al., Nature Communications (2023)
Product used: PepMix SARS-CoV-2 (S-RBD P.1 / Gamma) - Zika virus infection during pregnancy and vertical transmission: case reports and peptide-specic cellmediated immune responses
Soudeyns et al., Research Sqaure (2023)
Products used: PepMix CMVA (pp65), ZIKV (NS1) Ultra, ZIKV (C) Ultra, ZIKV (E) Ultra - YF17D-vectored Ebola vaccine candidate protects mice against lethal surrogate Ebola and yellow fever virus challenge
Lemmens et al., Vaccines (2023)
Product used: PepMix Zaire Ebola (GP/Kikwit-95) - Breadth and Durability of SARS-CoV-2-Specific T Cell Responses following Long-Term Recovery from COVID-19
Dang et al., Microbiology Spectrum (2023) - PMID: 37428088
Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NCAP), SARS-CoV-2 (VEMP), SARS-CoV-2 (VME1), SARS-CoV-2 (ORF10), SARS-CoV-2 (ORF9B)
Custom PepMix : SARS-CoV-2 ORF3a, ORF6, ORF7a, ORF7b, ORF8 - A localizing nanocarrier formulation enables multi-target immune responses to multivalent replicating RNA with limited systemic inflammation
Kimura et al., Molecular Therapy (2023) - PMID: 37403357
Product used: PepMix™ SARS-CoV-2 (Spike B.1.351 / Beta) - Unmodified rabies mRNA vaccine elicits high cross-neutralizing antibody titers and diverse B cell memory responses
Hellgren et al., Nature Communications (2023) - PMID: 37349310
Product used: PepMix Rabies virus (Glycoprotein) - Immunological imprinting of humoral immunity to SARS-CoV-2 in children
Dowell et al., Nature Communications - PMID: 37386081
Product used: PepMix™ SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron) & Influenza A (MP1 (H3N2)) - Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines
Han et al., Nature Nanotechnology (2023) - PMID: 37365276
Products used: PepMix™ SARS-CoV-2 (S-RBD) - Characterization of T cell responses to SARS-CoV-2 following infection and vaccination
Law, Dissertation (2023)
Products used: PepMix™SARS-CoV-2 (VME1), SARS-CoV-2 (VEMP), SARS-CoV-2 (NCAP) & SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2) - Oligosymptomatic long-term carriers of SARS-CoV-2 display impaired innate resistance but increased high-affinity anti-Spike antibodies
Montes-Cobos et al., iScience (2023)
Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) - Early evaluation of the safety, reactogenicity, and immune response after a single dose of modified vaccinia Ankara–Bavaria Nordic vaccine against mpox in children: a national outbreak response
Ladhani et al., The Lancet (2023) - PMID: 37336224
Product used: Custom PepMix - Third and Fourth Vaccine Doses Broaden and Prolong Immunity to SARSCoV-2 in Adult Patients with Immune-Mediated Inammatory Diseases
Cheung et al., Journal of Immunology (2023) - PMID: 37326480
Product used: PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.4 & BA.5 / Omicron) - T-Cell-Dominated Immune Response Resolves Protracted SARS-CoV-2 Infection in the Absence of Neutralizing Antibodies in an Immunocompromised Individual
Bunse et al., Microorganisms (2023) - PMID: 37375064
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2) - Engineered tumor-specific T cells using immunostimulatory photothermal nanoparticles
Sweeney et al., Cytotherapy (2023) - PMID: 37278683
Products used: custom PepMix - High efficacy of VLA2001 vaccine against SARSCoV-2 infection in non-human primates
Le Grand et al., Research Square (2023)
Products used: PepMix™ SARS-CoV-2 (S-RBD) & SARS-CoV-2 (NCAP) - A novel multi-antigenic parapoxvirus-based vaccine demonstrates efficacy in protecting hamsters and non-human primates against SARS-CoV-2 challenge
Reguzova et al., Research Square et al., (2023)
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (NCAP) - The Influence of Adjuvant Type on the Immunogenicity of RBD/N Cocktail Antigens as a Vaccine Candidate against SARS-CoV-2 Virus
Brzuska et al., Microbiology Spectrum (2023) - PMID: 37199661
Product used: PepMix™ SARS-CoV-2 (S-RBD) - The effects of exercise training for eight weeks on immune cell characteristics among breast cancer survivors
Echarri et al., Frontiers Sports Act. Living (2023) - PMID: 37252426
Product used: PepMix™ CMVA (pp65) & VZV (IE63) - Specific immune response to mRNA vaccines against COVID-19 in patients receiving allogeneic stem cell transplantation for myeloid malignancy was altered by immunosuppressive therapy
Macková et al., Leukemia Research (2023) - PMID: 37216792
Product used: PepMix™ SARS-CoV-2 (NCAP) - Robust Vaccine-Induced as Well as Hybrid B- and T-Cell Immunity across SARS-CoV-2 Vaccine Platforms in Peoplen with HIV
Verburgh et al., Microbiology Spectrum (2023) - PMID: 37166335
Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (NCAP) - A protective, single-visit TB vaccination regimen by co-administration of a subunit vaccine with BCG
Dijkman et al., Vaccines (2023) - PMID: 37160970
Product used: PepMix M. tuberculosis (ESAT-6), M. tuberculosis (PPE68), M. tuberculosis (EspA), PepMix M. tuberculosis (MPT64) & custom PepMix (for EspI, EspC, MPT70, MPT83), - Pre-pandemic SARS-CoV-2-specific IFN-γ and antibody responses were low in Ugandan samples and significantly reduced in HIV-positive specimens
Nantambi et al., Frontiers in Immunology (2023) - PMID: 37153598
Product used: PepMix™ SARS-CoV-2 (Spike Glycoproteins) - High-dimensional analysis of 16 SARS-CoV-2 vaccine combinations reveals lymphocyte signatures correlating with immunogenicity
Nuñez et al., Nature Immunology (2023) - PMID: 37095378
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (NCAP) - Impact of age and comorbidities on SARS-CoV-2 vaccine-induced T cell immunity
Dietz et al., Communications Medicine (2023) - PMID: 37095240
Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) - ESCRT recruitment to SARS-CoV-2 spike induces virus-like particles that improve mRNA vaccines
Hoffmann et al., Cell (2023) - PMID: 37146611
Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) - COVID-19 relapse associated with SARS-CoV-2 evasion from CD4+ T-cell recognition in an agammaglobulinemia patient
Morita et al., iScience (2023) - PMID: 37124420
Products used: 27 structural and non-structural PepMix SARS-CoV-2 proteins - Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy
Sharma et al., Journal for Immunotherapy of Cancer (2023) - PMID: 37072346
Product used: PepMix™ EBV (EBNA1), EBV (LMP1), EBV (LMP2) & EBV (BARF1) - Exercise mobilizes diverse antigen specific T-cells and elevates neutralizing antibodies in humans with natural immunity to SARS CoV-2
Baker et al., Brain, Behaviour & Immunity (2023) - PMID: 36743994
Products used: PepMix™ Human (Actin) & SARS-CoV-2 (Spike Glycoprotein) - A cell-free antigen processing system informs HIV-1 epitope selection and vaccine design
Sengupta et al., Journal of Experimental Medicine (2023) - PMID: 37058141
Product used: PepMix™ HIV-1 (NEF) Ultra & HIV-1 (Con B gag motif) - Long-Term Follow-Up after Adoptive Transfer of BK-Virus-Specific T Cells in Hematopoietic Stem Cell Transplant Recipients
Koldehoff et al., Vaccines (2023) - PMID: 37112757
Product used: PepMix™ BKV (capsid protein VP1) & BKV (large T antigen) - Metabolic interventions improve HBV envelope-specific T-cell responses in patients with chronic hepatitis B
Fu et al., Hepatology International (2023) - PMID: 36976426
Product used: PepMix™ HBV (Capsid Protein) Ultra & HBV (LEP) Ultra - Omicron BA.4/5 neutralization and T-cell responses in organ transplant recipients after Booster mrna vaccine: a Multicenter Cohort Study
Ferreira et al., Clinical Infectious Diseases (2023) - PMID: 36975097
Product used: PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.4 & BA.5 / Omicron) - Cytotoxic T Cells Targeting Spike Glycoprotein Are Associated with Hybrid Immunity to SARS-CoV-2
Phan et al., Journal of Immunology (2023) - PMID: 36961450
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (NCAP) - Combination Ad26.RSV.preF/preF protein vaccine induces superior protective immunity compared with individual vaccine components in preclinical models
Saeland et al., Vaccines (2023) - PMID: 36949051
Product used: PepMix HRSVA (Fusion Glycoprotein F0) - Humoral and cellular immunity to SARS-CoV-2 after vaccination with mRNA vaccines in PLWH with discordant immune response. Influence on the vaccine administered
López-Cortés et al., Frontiers in Immunology (2023) - PMID: 37006309
Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) - SARS-CoV-2 spike-ferritin-nanoparticle adjuvanted with ALFQ induces long-lived plasma cells and cross-neutralizing antibodies
Shrivastava et al., Vaccines (2023) - PMID: 36934088
Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) - Immunogenicity of COVID-eVax Delivered by Electroporation Is Moderately Impacted by Temperature and Molecular Isoforms
D'Alessio et al., Vaccines (2023) - PMID: 36992261
Product used: PepMix™ SARS-CoV-2 (S-RBD) - Spezifische T-Zellantwort und Immunevasion beim humanen Herpesvirus 6 und SARS-CoV-2
Hollaus, Dissertation (2023) - Engineering potent live attenuated coronavirus vaccines by targeted inactivation of the immune evasive viral deubiquitinase
Myeni et al., Nature Communications (2023)
Product used: PepMix MERS-CoV (Spike Glycoprotein) - Schistosoma mansoni infection alters the host pre-vaccination environment resulting in blunted Hepatitis B vaccination immune responses.
Muir et al., MedRxiv (2023)
Product used: PepMix HBV (Large envelope protein) - A systems immunology study comparing innate and adaptive immune responses in adults to COVID-19 mRNA and adenovirus vectored vaccines
Ryan et al., Cell Reports Medicine (2023)
Product used: PepMix Chimpanzee Adenovirus Y25 (Hexon Protein) - Incorporation of SARS-CoV-2 spike NTD to RBD Protein Vaccine Improves Immunity Against Viral Variants
Montgomerie et al., IScience (2023)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) - Pyrimidine de novo synthesis inhibition selectively blocks effector but not memory T cell development
Scherer et al., Nature Immunology (2023)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) - Carbohydrate fatty acid monosulphate: oil-in-water adjuvant enhances SARS-CoV-2 RBD nanoparticle-induced immunogenicity and protection in mice
Nanishi et al., Vaccines (2023)
Product used: PepMix SARS-CoV-2 (S-RBD) - Efficacy of an unmodified bivalent mRNA vaccine against SARS-CoV-2 variants in female small animal models
Corleis et al., Nature Communications (2023)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) - The role of the T-cell mediated immune response to Cytomegalovirus infection in intrauterine transmission
Soriano-Ramos et al., PLOS One (2023)
Products used: PepMix CMVA (IE-1) & CMVA (pp65) - Multimodal single‑cell analyses of peripheral blood mononuclear cells of COVID‑19 patients in Japan
Kashima et al., Scientific Reports (2023) - PMID: 36732528
Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NCAP), SARS-CoV-2 (VEMP), SARS-CoV-2 (VME1), ....ORF3a/6/7a/7b/8/9b/10 - Trimeric, APC-Targeted Subunit Vaccines Protect Mice against Seasonal and Pandemic Influenza
Tjärnhage et al., Journal of Virology (2023)
Products used: PepMix Influenza A (HA/Puerto Rico/8/1934 H1N1) & Influenza A (HA /California (H1N1)) - Anti-SARS-CoV-2 cellular response after 2 and 3 doses of BNT162b2 mRNA vaccine in lymphoma patients receiving anti-CD20 antibodies
Gressens et al., Vaccines (2023)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2) - Long COVID manifests with T cell dysregulation, inflammation, and an uncoordinated adaptive immune response to SARS-CoV-2
Yin et al., BioRxiv (2023)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) - Exercise mobilizes diverse antigen specific T-cells and elevates neutralizing antibodies in humans with natural immunity to SARS CoV-2
Baker et al., Brain Behaviour & Immunity - Health (2023)
Products used: PepMix Human (Actin) & SARS-CoV-2 (Spike Glycoprotein) - The HDAC inhibitor zabadinostat is a systemic regulator of adaptive immunity
Liu et al., Communications Biology (2023)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) - SARS-CoV-2 Omicron BA.4/BA.5 Mutations in Spike Leading to T Cell Escape in Recently Vaccinated Individuals
Emmelot et al., Viruses (2023) - Immunogenicity and safety of a two-dose regimen with hepatitis E virus vaccine in healthy adults in rural Bangladesh: A randomized, double-blind, controlled, phase 2/pilot trial
Øverbø et al., Vaccine (2023)
Product used: PepMix HEV (ORF2) - A linear DNA encoding the SARS-CoV-2 receptor binding domain elicits potent immune response and neutralizing antibodies in domestic cats
Conforti et al., Molecular Therapy (2023)
Product used: PepMix SARS-CoV-2 (S-RBD) - Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine as a heterologous booster dose in adult volunteers previously vaccinated with two doses of either COVISHIELD™ or COVAXIN: A Prospective double-blind randomised hase III clinical study
Thuluva et al., MedRxiv (2023)
Product used: PepMix SARS-CoV-2 (S-RBD) - The prospect of universal coronavirus immunity: a characterization of reciprocal and non-reciprocal T cell responses against SARS-CoV2 and common human coronaviruses
Soni et al., BioRxiv (2023) - Assessment of Immunogenicity and Efficacy of CV0501 mRNA-based Omicron COVID-19 Vaccination in Small Animal Models
Roth et al., BioRxiv (2023)
Product used: PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron) - Diminished responses to mRNA-based SARS-CoV-2 vaccines in individuals with rheumatoid arthritis on immune modifying therapies
Klebanoff et al., MedRxiv (2023)
Products used: CEFX Ultra SuperStim Pool, PepMix SARS-CoV-2 (Spike Glycoprotein) - An inactivated SARS-CoV-2 vaccine induced cross-neutralising persisting antibodies and protected upon challenge in small animals
Offersgaard et al., iScience (2023)
Products used: SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (S-RBD), SARS-CoV-2 (NCAP), SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2) - Safety, tolerability, and immunogenicity of a new SARS-CoV-2 recombinant Gamma variant RBD-based protein adjuvanted vaccine, used as heterologous booster in healthy adults: a Phase 1 interim report
Pasquevich et al., MedRxiv (2023)
Product used: PepMix SARS-CoV-2 (S-RBD P.1 / Gamma) - Single-dose YF17D-vectored Ebola vaccine candidate protects mice against both lethal surrogate Ebola and yellow fever virus challenge
Lemmens et al., BioRxiv (2023)
Products used: PepMix Zaire Ebola (GP/Kikwit-95), Yellow fever (NS4B)
Archive
Archive
- Persistence of SARS-CoV-2 neutralizing antibodies and anti-Omicron IgG induced by BNT162b2 mRNA vaccine in patients with autoimmune inflammatory rheumatic disease: An explanatory study in Japan
Yamaguchi et al., The Lancet (2023)
Product used: PepMix SARS-CoV-2 (Spike), SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron) - Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma
Keppler-Hafkemeyer et al., Nature Cancer (2023) - PMID: 36543907
Products used: PepMix SARS-CoV-2 (Spike B.1.617.2 / Delta), Human Adenovirus 5 (Hexon Protein), HCoV-OC43 (Spike Glycoprotein), SARS-CoV-2 (NCAP) - Listeria-vectored multi-antigenic tuberculosis vaccine protects C57BL/6 and BALB/c mice and guinea pigs against Mycobacterium tuberculosis challenge
Jia et al., Communications Biology (2022)
Products used: PepMix M. tuberculosis (Ag85B), M. tuberculosis (EspA), M. tuberculosis (EsxN), M. tuberculosis (TB8.4), M. tuberculosis (MPT64), custom PepMix (EsxH, EsxB, EsxA, ppe68) - A novel intradermal tattoo-based injection device enhances the immunogenicity of plasmid DNA vaccines
Gomez et al., Vaccines (2022) - PMID: 36543794
Products used: PepMix Zaire Ebola (GP/Mayinga-76) - Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulators
Sabatino et al., Multiple Sclerosis and Related Disorders (2022)
Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2) - Comprehensive Analysis of Epstein-BarrVirus LMP2A-Specific CD8+ and CD4+ T Cell Responses Restricted to Each HLA Class I and II Allotype Within an Individual
Jo et al., Immune Network (2022)
Product used: PepMix EBV (LMP2) - Accelerated waning of immune responses to a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases
Mrak et al., Journal of Autoimmunity (2022)
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron) - Characterization of Three Variants of SARS-CoV-2 In Vivo Shows Host-Dependent Pathogenicity in Hamsters, While Not in K18-hACE2 Mice
Toomer et al., Viruses (2022) - PMID: 36423193 - Product used: PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)
- High antibody levels and reduced cellular response in children up to one year after SARS-CoV-2 infection
Jacobsen et al., Nature Communications (2022)
Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2) - Allogeneic, Off-the-Shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high risk patients
Vasileiou et al., Haemtologica (2022)
Products used: PepMix SARS-CoV-2 (NCAP), SARS-CoV-2 (VME1), SARS-CoV-2 (VEMP), SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NS7A), SARS-CoV-2 (NS7B), SARS-CoV-2 (NS8) - SARS-CoV-2-Spike Antibody and T-Cell Responses Elicited by a Homologous Third mRNA COVID-19 Dose in Hemodialysis and Kidney Transplant Recipients
Panizo et al., Microorganisms (2022)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2) - Combined plasma cell-free DNA detection and IFNγ/TNF-α dual fluorospot assays for diagnosing active tuberculosis
Kim et al., Research Square (2022)
Products used: PepMix M. tuberculosis (ESAT-6), M. tuberculosis (CFP-10), M. tuberculosis (Ag85B) - Four-Parameter FluoroSpot Assay Reveals That the Varicella Zoster Virus Elicits a Robust Memory T Cell IL-10 Response throughout Childhood
Nilsson et al., Journal of Virology (2022) - PMID: 36314824
Products used: PepMix VZV (IE63) & VZV (gE) - Characterization of B-cell and T-cell responses to a tetravalent dengue purified inactivated vaccine in healthy adults
Friberg et al., Vaccines (2022) - PMID: 36316335
Product used: PepMix Dengue 1 (E) Ultra - Reduced humoral but stable cellular SARS-CoV-2-specific immunity in liver transplant recipients in the first year after COVID-19
Kirchner et al., PLoS One (2022) - PMID: 36322587
Products used: PepMix Pan-SARS-CoV-2 Select, SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), SARS-CoV-2 (NCAP), SARS-CoV-2 (VEMP), HCoV-229E (Spike Glycoprotein), HCoV-OC43 (Spike Glycoprotein), HRSVB (Nucleocapsid Protein N), Influenza A (M1) Ultra - Efficacy of mucosal vaccination using a protozoan parasite as a vehicle for antigen delivery: IgG and neutralizing response after rectal administration of LeCoVax-2, a candidate vaccine against COVID-19
Epis et al., Pharmacological Research (2022) - PMID: 36336215
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) - Immunological signature in human cases of monkeypox infection in 2022 outbreak: an observational study
Agrati et al., The Lancet (2022)
Products used: PepMix Vaccinia virus (MVA105L), Vaccinia virus (MVA074R), Vaccinia virus (MVA121L) - SARS-CoV-2 Spike-specific IFN-gamma T-cell Response After COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant
Imhof et al., Infectious Disease (2022)
Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2) - Chimeric mRNA based COVID-19 vaccine induces protective immunity against Omicron and Delta variants
Hu et al., Molecular Therapy (2022)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) - Humoral and Cellular Responses to a Delayed Fourth SARS-CoV-2 mRNA-Based Vaccine in Weak Responders to 3 Doses Kidney Transplant Recipients
Del Bello et al., Vaccines (2022) - PMID: 36146517
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2) - A third dose of the unmodified COVID-19 mRNA vaccine CVnCoV enhances quality and quantity of immune responses
Lenart et al., Molecular Therapy (2022)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) - A Tale Of T ale Of Two Transgenes: Aa ansgenes: Aav-Dystr v-Dystrophin And Aa ophin And Aav-Spike Reveal Common Themes For Gene Therapy And Vaccines
Greer, Dissertation (2022)
Products used: PepMix SARS-CoV-2 (Spike Glycoprotein) and SARS-CoV-2 (Spike B.1.1.7 / Alpha) - Immunogenicity of SARS-CoV-2 spike antigens derived from Beta & Delta variants of concern
Akache et al., Vaccines (2022)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) - Artificial Cell Membrane Polymersome-Based Intranasal Beta Spike Formulation as a Second Generation Covid-19 Vaccine
Lam et al., ACS Nano (2022) -
Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2) - Signs of immunosenescence correlate with poor outcome of mRNA COVID-19 vaccination in older adults
Palacios-Pedrero et al., Nature Aging (2022)
Product used: PepMix SARS-CoV-2 (NCAP) - Rekombinowane cząstki wirusopodobne jako potencjalne antygeny szczepionkowe przeciwko wirusowi Zika
Brzuska, Dissertation (2022)
Products used: PepMix ZIKV (E) Ultra and ZIKV (M) Ultra - Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial
Gunst et al., Nature Medicine (2022) - PMID: 36253609
Product used: PepMix HIV Gag Ultra - NVX-CoV2373-induced cellular and humoral immunity towards parental SARS-CoV-2 and VOCs compared to BNT162b2 and mRNA-1273-regimens
Hielscher et al., Journal of Clinical Virology (2022) - PMID: 36279695
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) - Immune Response after the Fourth Dose of SARS-CoV-2 mRNA Vaccine Compared to Natural Infection in Three Doses’ Vaccinated Solid Organ Transplant Recipients
Busà et al., Vaccines (2022) - PMID: 36298854
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NCAP) and CEFX Ultra SuperStim Pool - Proinflammatory Innate Cytokines and Distinct Metabolomic Signatures Shape the T Cell Response in Active COVID-19
Binayke et al., Vaccines (2022) - PMID: 36298628
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2) - Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose
Belik et al., Research Square (2022)
Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron), and SARS-CoV-2 (Spike B.1.1.529 / BA.2 / Omicron) - Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8+ T cell immunity
Rosás-Umbert et al., Nature Communications (2022)
Products used: PepMix HIV-1 (GAG) Ultra, HIV-1 (ENV) Ultra, HIV-1 (NEF) Ultra, HIV-1 (POL) Ultra - Ablation of CD8+ T cell recognition of an immunodominant epitope in SARS-CoV-2 Omicron variants BA.1, BA.2 and BA.3
Swaminathan et al., Nature Communications
Products used: PepMix SARS-CoV-2 (NCAP), SARS-CoV-2 (NS6), SARS-CoV-2 (NS7A), SARS-CoV-2 (NS7B), SARS-CoV-2 (NS8), SARS-CoV-2 (ORF9B), SARS-CoV-2 (ORF10), SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (VEMP), SARS-CoV-2 (VME1), SARS-CoV-2 (Y14) - Accumulation of mutations in antibody and CD8 T cell epitopes in a B cell depleted lymphoma patient with chronic SARS-CoV-2 infection
Khatamzas et al., Nature Communication (2022)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) - Evidence of premature lymphocyte aging in people with low anti-spike antibody levels after BNT162b2 vaccination
Huang et al., iScience (2022) - PMID:
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) - SARS-CoV-2-specicific humoral immunity in convalescent patients with mild COVID-19 is supported by CD4+ T-cell help and negatively correlated with Alphacoronavirus-specific antibody titer
Odendahl et al., Immunology Letters (2022)
Product used: PepMix CMVA (pp65) - Comparison of the Immune Responses to COVID-19 Vaccines in Bangladeshi Population
Sarker et al., Vaccines (2022)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) - Comparison between enzyme‐linked immunospot assay and intracellular cytokine flow cytometry assays for the evaluation of T cell response to SARS‐CoV‐2 after symptomatic COVID‐19
Villemonteix et al., Immunity, Inflammation and Disease (2022) - PMID
PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NCAP) - Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models
Hajnik et al., Science Translational medicine (2022) - PMID: 36103514
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) - A Recombinant VSV-Based Bivalent Vaccine Effectively Protects against Both SARS-CoV-2 and Influenza A Virus Infection
Ao et al., Journal of Virology (2022) - PMID: 36069551
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1) - SARS-CoV-2 mRNA-vaccine candidate; COReNAPCIN, induces robust humoral and cellular immunity in mice and non-human primates
Alimohammadi et al., Vaccines (2022) - PMID: 36056015
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) - SARS‑CoV‑2‑reactive IFN‑γ‑producing CD4+ and CD8+T cells in blood do not correlate with clinical severity in unvaccinated critically ill COVID‑19 patients
Olea et al., Scientific Reports (2022) - PMID: 35995830 - Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response
Stort et al., Oncoimmunology (2022)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) - Humoral and cellular responses to mRNA-based COVID-19 booster vaccinations in patients with solid neoplasms under active treatment
Su et al., ESMO Open (2022)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) - Protective Immunity of COVID-19 Vaccination with ChAdOx1 nCoV-19 Following Previous SARS-CoV-2 Infection: A Humoral and Cellular Investigation
Azamor et al., Viruses (2022) - PMID: 36146723
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) - Antibody and T-cellular response to COVID-19 booster vaccine in SARS-CoV-1 survivors
Lu et al., Clinical Immunology (2022)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) - Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an openlabel extension study
Mrak et al., Annals of Rheumatic Disease (2022) - PMID: 35977809 - Gene Transfer in Adeno-Associated Virus Seropositive Rhesus Macaques Following Rapamycin Treatment and Subcutaneous Delivery of AAV6, but Not Retargeted AAV6 Vectors
Stone et al., Human Gene Therapy (2022) - SARS-CoV-2-specific CD4+ T cell longevity correlates with Th17-like phenotype
Terahara et al., iScience (2022) - PMID: 35992306 - Japanese encephalitis virus infection in its natural amplification and reservoir host, the pig
Redant, Dissertation (2022) - Secreted heat shock protein gp96-Ig and OX40L-Fc combination vaccine enhances SARS-CoV-2 Spike (S) protein-specific B and T cell immune responses
Padula et al., Vaccine: X (2022) - PMID: 35936992
Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SU1 & SU2) - Analysis of the Specific Immune Response after the Third Dose of mRNA COVID-19 Vaccines in Organ Transplant Recipients: Possible Spike-S1 Reactive IgA Signature in Protection from SARS-CoV-2 Infection
Miele et al., Microorganisms (2022)
Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SU1 & SU2) & SARS-CoV-2 NCAP - mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant
Nanishi et al., Communications Biology (2022) - Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose
Renia et al., Nature Communications - The long term vaccine-induced anti-SARS-CoV-2 immune response is impaired in quantity and qualityunder TNFα blockade
Geisen et al., Journal of Medical Virology (2022) - PMID: 35945627 - Clinical outcomes, immunogenicity, and safety of BNT162b22 Vaccine in Primary Antibody Deficiency
Milota et al., Authorea (2022) - DNA-Vaccine-Induced Immune Response Correlates with Lower Viral SARS-CoV-2 Titers in a Ferret Model
Compagnone et al., Vaccines (2022) - PMID: 35893826 - SARS-CoV-2 Vaccine-Induced Antibody and T-Cell Response in SARS-CoV-1 Survivors
Duan et al., Cell Reports (2022) - Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA1273-boosting with homologous COVID-19 vaccine regimens
Klemis et al., Nature Communications (2022) - Brief Research Report: Anti-SARS-CoV-2 Immunity in Long Lasting Responders to Cancer Immunotherapy Through mRNA-Based COVID-19 Vaccination
Sistere-Oro et al., Frontiers in Immunology (2022) - Analysis of the humoral and cellular response after the third COVID-19 vaccination in patients with autoimmune hepatitis
Hartl et al., Liver International (2022) - PMID: 35840342 - Respiratory mucosal immunity against SARS-CoV-2 following mRNA vaccination
Tang et al., Science Immunology (202) - PMID: 35857583 - Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies
Minnar et al., Journal of Immunology (2022) - PMID: 35764364
Product used: PepMix HPV 16 (E7) - Robust SARS-COV-2-specific T-cell immune memory persists long-term in immunocompetent individuals post BNT162b2 double shot
Papadopoulou et al., Heliyon (2022) - PMID: 35815135
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) - A novel SARS-CoV-2 subunit vaccine engineered on an immune-activating platform technology
Quinlan et al., Human Vaccines & Immunotherapeutics (2022) - PMID: 35801956
Product used: PepMix SARS-CoV-2 (Spike-RBD) - Safety and immunogenicity of intramuscular, single- dose V590 (rVSV-SARS-CoV-2 Vaccine) in healthy adults: Results from a phase 1 randomised, double- blind, placebo-controlled, dose-ranging trial
Robbins et al., The Lancet (2022)
Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) - A Lymph Node Targeted Adjuvant and Engineered Subunit Vaccine Promotes Potent Immunity to Epstein-Barr Virus in HLA-expressing Mice
Dasari et al., Research Square (2022)
Product used: PepMix EBV (GP350/GP340) - Longitudinal T Cell Responses against Ancestral, Delta, and Omicron SARS-CoV-2 Variants determined by Rapid Cytokine Release Assay in Whole Blood
Oliver et al., Immunohorizons (2022) - PMID: 35750357
Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SU1 & SU2), SARS-CoV-2 (Spike B.1.617/Delta), SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron) - Long-Lived Immunity in SARS-CoV-2-Recovered Children and Its Neutralizing Capacity Against Omicron
Sieber et al., Frontiers in Immunology (2022) - PMID: 35663948
Product used: PepMix SARS-CoV-2 (VME1), SARS-CoV-2 (VEMP), SARS-CoV-2 (NCAP), SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron) - Natural Immunity against HIV-1: Progression of Understanding after Association Studies
Ma Luo, Viruses (2022)
Product used: PepMix HIV-1 (GAG) Ultra - In Vitro Generation of BK polyomavirus-specifc T cells for adoptive cell therapy in refractory cystitis hemorrhagic patients after hematopoietic stem cell transplantation
Najafabadi et al., BMC Immunology (2022) - PMID: 35689183
Product used: PepMix BKV (Capsid Protein VP1) - In Vitro Generation of BK polyomavirus-specifc T cells for adoptive cell therapy in refractory cystitis hemorrhagic patients after hematopoietic stem cell transplantation
- Najafabadi et al., BMC Immunology (2022) - PMID: 35689183
Product used: - T-cell proliferation assay for the detection of SARS-CoV-2-specific T-cells
Chu et al., Clinical Chimica Acta (2022) - PMID: 35690083
Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NCAP), SARS-CoV-2 (VME1) - Pre-existing adaptive immunity to the RNA-editing enzyme Cas13d in humans
Tang et al., Nature Medicine (2022) - PMID: 35668177
Product used: PepMix S. pyogenes (CAS9)_2 subpools - A DNA vaccine candidate delivered by an electroacupuncture machine provides protective immunity against SARS-CoV-2 infection
Tzeng et al., Vaccines (2022) - Chimeric Virus-like Particle-Based COVID-19 Vaccine Confers Strong Protection against SARS-CoV-2 Viremia in K18-hACE2 Mice
Kaewborisuth et al., Vaccines (2022) - Cellular Immune Response after Vaccination with an Adjuvanted, Recombinant Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients
Koldehoff et al., Vaccines (2022) - SARS-CoV-2 OmicronBA.1 variantbreakthrough infections in nursing home residentsafter an homologousthird dose of the Comirnaty® COVID-19 vaccine: Looking for correlates of protection
Torres et al., Journal of Medical Virology (2022)
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2) - Durable immunogenicity, adaptation to emerging variants and low dose efficacy of AAV-based COVID19 platform in macaques
Zabaleta et al., Molecular Therapy (2022)
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2) - Enhanced Humoral Immune Response After COVID-19 Vaccination in Elderly Kidney Transplant Recipients on Everolimus Versus Mycophenolate Mofetil–containing Immunosuppressive Regimens
de Boer et al., Translantation (2022) - PMID: 35546527
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2) - SARS-CoV2 wild type and mutant specific humoral and T cell immunity is superior after vaccination than after natural infection
Richardson et al., PLoS One (2022) - PMID: 35468147
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (Spike B.1.1.7 / Alpha), SARS-CoV-2 (Spike B.1.351 / Beta), SARS-CoV-2 (Spike P.1 / Gamma), SARS-CoV-2 (Spike B.1.617.2 / Delta) - Two DNA vaccines protect against severe disease and pathology due to SARS-CoV-2 in Syrian hamsters
Babuadze et al., NPJ Vaccines (2022) - PMID: 35474311
Product used: PepMix™ SARS-CoV (Spike Glycoprotein) - Transcriptomic analysis reveals optimal cytokine combinations for SARS-CoV-2 Specific T cell therapy products
Durkee-Shock et al., Molecular Therapy: Methods & Clinical Development (2022) - Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod
Cabeza et al., Neurology: Neuroimmunology & Neuroinflammation - PMID: 35523569
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2) - Children and Adults With Mild COVID-19: Dynamics of the Memory T Cell Response up to 10 Months
Kaaijk et al., Frontiers in Immunology (2022)
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NCAP), HCoV-OC43 (Spike Glycoprotein) - Strong peak immunogenicity but rapid antibody waning following third vaccine dose in elderlyresidents of care homes
Tut et al., Research Square (2022)
Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) - Discordant antibody and T cell responses to the SARS-CoV-2 Omicron variant in COVID-19 mRNA vaccine recipient
Woldemeskel et al., Clinical Infectious Diseases (2022) - PMID: 35438751
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (S-RBD B.1.1.529 / Omicron) - USA SARS-CoV-2 Epsilon Variant: Though Highly Transmissible has an Adjusted Muted Host T-Cell Response
Plummer et al., Clinical Infectious Diseases (2022) - PMID: 35438777
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (Spike B.1.429 / Epsilon) - mRNA booster vaccination protects extremely aged mice against the SARS-CoV-2 Omicron variant
Dowling et al., Research Square (2022)
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (S-RBD B.1.1.529 / Omicron)
- Evaluation of overcoming Limited migration and Enhancing Cytomegalovirus-specific dendritic cell Vaccines with Adjuvant TEtanus pre-conditioning in patients with newlydiagnosed glioblastoma
Randazzo et al., Clinical Trials (2022)
Product used: PepMix™ CMVA (pp65) - Viral Evolution and Immunology of SARS-CoV-2 in a Persistent Infection after Treatment with Rituximab
van der Moerden et al., Viruses (2022) - Dynamics of SARS-CoV-2-Spike-reactive antibody and T-cell responses in chronic kidney disease patients within three months after COVID-19 full vaccination
Panizo et al., Clinical Kidney Journal (2022)
Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) - Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): a single blind, randomized, non-inferiority trial
Pannus et al., MedRxiv (2022) - Safety and tolerability of AAV8 delivery of abroadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial
Casazza et al., Nature Medicine (2022) - PMID: 35411076
Product used: PepMix™ AAV8 (capsid protein) - NK cells limit therapeutic vaccine–induced CD8+ T cell immunity in a PD-L1–dependent manner
Diniz et al., Vaccines (2022) - PMID : 35417187 - Temporal changes in T cell subsets and expansion of cytotoxic CD4+ T cells in the lungs in severe COVID-19
Kaneko et al., Clinical Immunology (2022) - PMID: 35364330
Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) - T cell response against SARS-CoV-2 persists after one year in patients surviving severe COVID-19
Venet et al., EBioMedicine (2022) - PMID: 35349827
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NCAP), SARS-CoV-2 (VME1) - CD4+ T Cell Dysfunction in Severe COVID-19 Disease is TNFalpha/TNFRI-Dependent
Popescu et al., American Journal of Respiratory Critical Care Medicine - PMID: 35348444
Products used: PepMix™ SARS-CoV-2 (NCAP), SARS-CoV-2 (VEMP), SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2) - The Quality of Anti-SARS-CoV-2 T Cell Responses Predicts the Neutralizing Antibody Titer in Convalescent Plasma Donors
Kroemer et al., Front Public Health (2022) - PMID: 35372242
Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NCAP), SARS-CoV-2 (VME1) - High antibody and reduced cellular response in children up to one year after SARS-CoV-2 infection
Jacobsen et al., Research Square (2022)
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2) - Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study
Lim et al., Nature Cancer (2022) - PMID : 35332334
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2) - Self-amplifying mRNA SARS-CoV-2 vaccines raise cross-reactive immune response to variants and prevent infection in animal models
Palladino et al., Methods and Clinical Development (2022)
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (NCAP) - Evolution of Humoral and Cellular Immunity in Two COVID-19 Breakthrough Infections After BNT162b2 Vaccine
Gallais et al., Frontiers in Immunology (2022) - PMID: 35281046
Products used: PepMix™ SARS-CoV-2 (Spike B.1.1.7 / Alpha), SARS-CoV-2 (Spike B.1.351 / Beta), SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2) - SARS‐CoV‐2 vaccination response in patients with autoimmune hepatitis and autoimmune cholestatic liver disease
Duengelhoef et al., United European Gastroenterol Journal (2022) - PMID: 35289983
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) - Novel T cell interferon gamma release assay (IGRA) using spike recombinant protein for COVID19 vaccine response and Nucleocapsid for SARS-Cov2 response
Renaudineau et al., Clinical Immunology (2022) - PMID: n.a.
Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2) - Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination
Sheng et al., Journal of the Formosan Medical Association (2022) - PMID: 35305895
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2) - Modular capsid decoration boosts adenovirus vaccine-induced humoral and cellular immunity against SARS-CoV-2
Dicks et al., BioRxiv (2022)
Products used: PepMix™ SARS-CoV-2 (S-RBD), SARS-CoV-2 (Spike Glycoprotein) - SARS-CoV- 2 (COVID- 19)-specific T cell and B cell responses in convalescent rheumatoid arthritis: Monozygotic twins pair case observation
Arruda et al., Immunology (2022) - PMID: 35212005
Products used: PepMix™ SARS-CoV-2 (NCAP) & SARS-CoV-2 (Spike Glycoprotein) - Humoral and Cellular Immune Responses of Solid Organ Transplant Patients on Belatacept to Three Doses of mRNA-Based Anti-SARS-CoV-2 Vaccine
Abravanel et al., Vaccines (2022)
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) - Three-month follow-up of heterologous vs homologous third vaccination in kidney transplant recipients
Heinzel et al., MedRxiv (2022)
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) - Limited Recognition of Highly Conserved Regions of SARS-CoV-2
Swaminathan et al., Microbiology Spectrum (2022) - PMID: 35196796
Products used: PepMix™ SARS-CoV-2 (Nsp12), SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (NCAP) - Assessment of humora land cellular immune responses to SARSCoV-2 vaccination (BNT162b2) inimmunocompromised renal allograft recipients
Zhang et al., Transplant Infectious Diseases (2022)
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) - Tacrolimus-resistant SARS-CoV-2-specific T-cell products to prevent and treat severe COVID-19 in immunosuppressed patients
Peter et al., Molecular Therapy (2022)
Products used: PepMix™ SARS-CoV-2 (NCAP), SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), SARS-CoV-2 (VEMP), SARS-CoV-2 (VME1), SARS-CoV-2 (AP3A), SARS-CoV-2 (NS7A), SARS-CoV-2 (NS7B), SARS-CoV-2 (ORF9B), SARS-CoV-2 (ORF10), SARS-CoV-2 (Spike B.1.1.7 / Alpha), SARS-CoV-2 (Spike B.1.351 / Beta), SARS-CoV-2 (Spike B.1.617.2 / Delta), SARS-CoV-2 (Spike B.1.1.529 / Omicron), CMVA (pp65) - Evaluation of IL-1β and IL-6 expression following EBNA-1 and BRLF-1 peptide treatment in Epstein Barr virus-positive multiple sclerosis patients
Kianfar et al., Intervirology (2022) - Performance comparison of a fow cytometry immunoassay for intracellular cytokine staining and the QuantiFERON® SARS-CoV-2test for detection and quantifcation of SARS-CoV-2-Spike-reactiveIFN-γ-producing T cells after COVID-19 vaccination
Tormo et al., European Journal of Clinical Microbiology & Infectious Diseases (2022) - PMID: 35165804
Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) - SARS-CoV-2-specific T cells generated for adoptive immunotherapy are capable of recognizing multiple SARS-CoV-2 variant
Panikkar et al., Pathogens (2022) - PMID: 35157735
Products used: PepMix™ SARS-CoV-2 (AP3A), SARS-CoV-2 (NCAP), SARS-CoV-2 (VME1), SARS-CoV-2 (Spike Glycoprotein) - Polyfunctional pathogen-specific CD4+ T cells reside in the lungs and tumors of NSCLC patients
Oja et al., BioRxiv (2022)
Products used: PepMix™ HRSVB (Fusion Glycoprotein F0) & HRSVB (MSG) - T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all prior infected and vaccinated individuals
Vivek Naranbhai et al., MedRxiv (2022) - PMID: 35018386
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NCAP), SARS-CoV-2 (VME1), SARS-CoV-2 (VEMP), SARS-CoV-2 (AP3A), SARS-CoV-2 (Spike B.1.617.2 / Delta) - Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys
Amarendra Pegu et al., Cell Report (2022) - PMID: 34986348
Products used: PepMix™ HIV-1 (ENV) Ultra - Bystander CD4+ T cells infiltrate human tumors and are phenotypically distinct
Shamin Li et al., OncoImmunology (2022) - PMID: n.a.
Products used: PepMix™ CMVA (pp65) - Innate and adaptive immune defects associated with lower SARS-CoV-2 BNT162b2 mRNA vaccine response in elderly people
Joana Vitallé et al., medRxiv (2022) - PMID: n.a.
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) - Temporary hold of mycophenolate boosts SARS-CoV-2 vaccination-specific humoral and cellular immunity in kidney transplant recipients
Eva Schrezenmeier et al., MedRxiv (2022)
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) - Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents
Nina Koerber et al., Nature Communications (2022)
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) - Persistent T-Cell Reactivity in a Seronegative Patient after SARS-CoV-2 Infection and One Vaccination
Nico Andreas et al., Vaccines (2022)
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2) - Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity
Shinya Abe et al., Immunotherapy of Cancer (2022)
Products used: PepMix™ HIV-1 (GAG) Ultra - Development of an effective immune response in adults with Down Syndrome 2 after SARS-CoV-2 vaccination
Laura Esparcia-Pinedo et al., MedRxiv (2022)
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), SARS-CoV-2 (VME1), SARS-CoV-2 (NCAP), SARS-CoV-2 (Nsp5) - Wnt activation promotes memory T cell polyfunctionality via epigenetic regulator PRMT1
Bo-Yi Sung et al., Journal of Clinical Investigation (2022) - PMID: 35040433
Products used: PepMix™ CMVA (pp65) - Clinical and Immunological Characteristics for BK Polyomavirus- associated Nephropathy after Kidney Transplantation
Tanaya Siripoon et al., Research Square (2022)
Products used: PepMix™ BKV (capsid protein VP1), BKV (large T antigen) - T cell response to intact SARS-CoV-2 includes coronavirus cross-reactive and variant-specific components
Lichen Jing et al., MedRxiv et al., (2022)
Products used: PepMix™ HCoV-OC43 (Spike Glycoprotein) - Persistently reduced humoral and cellular immune response following third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients
Bajwa et al., MedRxiv (2022) - Antibody and T cell responses to SARS-CoV-2 mRNA vaccines during maintenance therapy for immune-mediated inflammatory diseases
Dayam et al., MedRxiv (2022) - Infection or a third dose of mRNA vaccine elicit neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients
Charmetant et al., Science Translational Medicine (2022) - PMID: 35103481
Products used: PepMix™ SARS-CoV-2 (NCAP), SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (VME1) - Concordance of B and T cell responses to SARS-CoV-2 infection, irrespective of symptoms suggestive of COVID-19
Österdahl et al., MedRxiv (2022) - Differential localization and limited cytotoxic potential of duodenal CD8+ T cells
Mvaya et al., JCI Insight (2022) - PMID: 35132966
Products used: PepMix™ HIV-1 (POL), HIV-1 (GAG) & HIV-1 (NEF) - Full efficacy and long-term immunogenicity induced by the SARS-CoV-2 vaccine candidate MVA-CoV2-S in mice
Lázaro-Frías et al., Vaccines (2022)
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) - mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron
Gagne et al., BioRxiv (2022)
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2) - A Co-stimulatory CAR Improves TCR-based Cancer Immunotherapy
Omer et al., Cancer Immunology Research (2022) - PMID: 35176142
Products used: PepMix™ EBV (EBNA1), EBV (LMP1), EBV (LMP2) - Effectiveness and durability of the mRNA vaccine-induced SARSCoV-2-specific humoral and cellular immunity in severe asthma patients on biological therapy
Prodrazil et al., MedRxiv (2022)
Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) - Impaired Anti-SARS-CoV-2 Humoral and Cellular Immune Response Induced by Pfizer-BioNTech BNT162b2 mRNA Vaccine in Solid Organ Transplanted Patients
Monica Miele et.al., American Journal of Transplantation (2021) - PMID: 34058052 - CD8+ T Cells Specific for an Immunodominant SARS-CoV-2 Nucleocapsid Epitope Cross-React With Selective Seasonal Coronaviruses
Katie E Lineburg et.al., Immunity (2021) - PMID: 33945786 - Prime hAd5 Spike plus Nucleocapsid Vaccination Induces Ten-Fold Increases in Mean T-Cell Responses in Phase 1 Subjects that are Sustained Against Spike Variants
Pete Sieling et.al., medRxiv (2021) - PMID: n.a. - Gene Transfer in Adeno-Associated Virus Seropositive Rhesus Macaques Following Rapamycin Treatment and Subcutaneous Delivery of AAV6, but Not Retargeted AAV6 Vectors
Stone et al., Human Gene Therapy (2021) - PMID: 32998579 - Preclinical Evaluation of a SARS-CoV-2 mRNA Vaccine PTX-COVID19-B
Jun Liu et.al., bioRxiv (2021) - PMID: n.a. - A Lymph Node-Targeted Amphiphile Vaccine Induces Potent Cellular and Humoral Immunity to SARS-CoV-2
Martin P Steinbuck et.al., Sci Adv. (2021) - PMID: 33446655 - SARS-CoV-2 Spike Glycoprotein Vaccine Candidate NVX-CoV2373 Immunogenicity in Baboons and Protection in Mice
Jing-Hui Tian et.al., Nat Commun (2021) - PMID: 33446655 - Safety and Immunogenicity of the SARS-CoV-2 BNT162b1 mRNA Vaccine in Younger and Older Chinese Adults: a Randomized, Placebo-Controlled, Double-Blind Phase 1 Study
Jingxin Li et.al., Nat Med. (2021) - PMID: 33888900 - BNT162b Vaccines Protect Rhesus Macaques From SARS-CoV-2
Annette B Vogel et.al., Nature (2021) - PMID: 33524990 - Older Adults Lack SARS CoV-2 Cross-Reactive T Lymphocytes Directed to Human Coronaviruses OC43 and NL63es
Giulietta Saletti et.al., Sci Rep. (2021) - PMID: 33293664 - SARS-CoV-2 Variants of Concern Partially Escape Humoral but not T-Cell Responses in COVID-19 Convalescent Donors and Vaccinees
Daryl Geers et.al., Sci Immunol. (2021) - PMID: 34035118 - COVID-19 Immune Signatures Reveal Stable Antiviral T Cell Function Despite Declining Humoral Responses
Agnes Bonifacius et.al., Immunity (2021) - PMID: 33567252 - IL-33 Expression in Response to SARS-CoV-2 Correlates With Seropositivity in COVID-19 Convalescent Individuals
Michal A Stanczak et.al., Nat Commun. (2021) - PMID: 33837219 - A Highly Specific Assay for the Detection of SARS-CoV-2-Reactive CD4 + and CD8 + T Cells in COVID-19 Patients
Henning Zelba et.al., J Immunol. (2021) - PMID: 33298615 - SARS-CoV-2-Reactive T Cells in Healthy Donors and Patients With COVID-19
Julian Braun et.al., Nature (2021) - PMID: 32726801 - Functional Characterization of CD4+ T Cell Receptors Crossreactive for SARS-CoV-2 and Endemic Coronaviruses
Arbor G Dykema et.al., J Clin Invest. (2021) - PMID: 33830946 - Culture Media Optimization for Chinese Hamster Ovary Cell Growth and Expression of Recombinant Varicella-Zoster Virus Glycoprotein E
Kwang Sung Kim et.al., Cytotechnology (2021) - PMID: 33897103 - SARS-CoV-2 Protein Subunit Vaccination of Mice and Rhesus Macaques Elicits Potent and Durable Neutralizing Antibody Responses
Marco Mandolesi et.al., Cell Reports Medicine (2021) - PMID: 33842900 - SARS-CoV-2 mRNA Vaccine BNT162b2 Elicited a Robust Humoral and Cellular Response Against SARSCoV-2 Variants
Daniele Lilleri et.al., Research Square (2021) - PMID: n.a. - Children Develop Strong and Sustained Cross-Reactive Immune Responses Against Spike Protein Following SARS-CoV-2 Infection, With Enhanced Recognition of Variants of Concern
Alexander C. Dowell et.al., medRxiv (2021) - PMID: n.a. - Comorbid illnesses are associated with altered adaptive immune responses to SARS-CoV-2
Krystle K.Q. Yu et.al., JCI Insight (2021) - PMID: 33621211 - Targeting SARS-CoV-2 Receptor-Binding Domain to Cells Expressing CD40 Improves Protection to Infection in Convalescent Macaques
Romain Marlin et.al., Nature Communications (2021) - PMID: n.a. - Characterization of Recombinant Gorilla Adenovirus HPV Therapeutic Vaccine PRGN-2009
Samuel T. Pellom et.al., JCI Insight (2021) - PMID: 33651712 - Cytomegalovirus-Specific T-Cell Reconstitution Following Letermovir Prophylaxis after Hematopoietic Cell Transplantation
Danniel Zamora et.al., In Press, Journal Pre-proof (2021) - PMID: 33657225 - Optimization of Zika DNA Vaccine by Delivery Systems
Yun Ha Lee et.al., Virology (2021) - PMID: 33780719 - Human Cytomegalovirus and Epstein-Barr Virus Specific Immunity in Patients With Ulcerative Colitis
Rachele Ciccocioppo et.al., Clinical and Experimental Medicine (2021) - PMID: 33772380 - Longitudinal Analysis of Human Memory T-Cell Response according to the Severity of Illness up to 8 Months after SARS-CoV-2 Infection
Chang Kyung Kang et.al., The Journal of Infectious Diseases (2021) - PMID: 33755725 - Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection
Jianmin Zuo et.al., Nature (2021) - PMID: 33674800 - SARS-CoV-2 Spike Protein Arrested In The Closed State Induces Potent Neutralizing Responses
George W. Carnell et.al., bioRxiv (2021) - PMID: n.a. - First Report Demonstrating The Safety And Immunogenicity Of The SARS-COV-2 BNT162b1 mRNA Vaccine In Younger And Older Chinese Adults: A Randomized, Placebo-Controlled, Observer-Blind Phase I Study
Fengcai Zhu et.al., Research Square (2021) - PMID: n.a. - Validation of an IFN-Gamma ELISpot Assay to Measure Cellular Immune Responses Against Viral Antigens in Non-Human Primates
Fan Yang et.al., Gene Ther. (2021) - PMID: 33432123 - Poor Anti-SARS-CoV-2 Humoral and T-cell Responses After 2 Injections of mRNA Vaccine in Kidney Transplant Recipients Treated With Belatacept
Nathalie Chavator et al., Transplantation, (2021) - SARS-CoV-2 Specific Memory T Cell Epitopes Identified in COVID-19-Recovered Subjects
Juan Zhao et al., Virus Res, (2021) - Intrafamilial Exposure to SARS-CoV-2 Associated with Cellular Immune Response without Seroconversion, France
Floriane Gallais et al., Emerg Infect Dis, (2021) - SARS-CoV2 Mutant-Specific T Cells and Neutralizing Antibodies After Vaccination and up to 1 Year After Infection
Richardson, J.R. et al., ISAR Bioscience, (2021) - COVID-19 Subunit Vaccine with a Combination of TLR1/2 and TLR3 Agonists Induces Robust and Protective Immunity
Soo-Kyung Jeong et al., Vaccines, (2021) - M2-Deficient Single-Replication Influenza Vaccine–Induced Immune Responses Associated With Protection Against Human Challenge With Highly Drifted H3N2 Influenza Strain
Joseph Eiden et al., J Infect Dis, (2021) - Impairment of CD4+ T and Memory B Cell Responses but Normal Memory CD8+T-Cell Activation on Crohn’s Disease after COVID-19 Vaccination: A Twin Case
Fabiana Gil-Melgaço et al., Viruses, (2021) - Weak Immunogenicity of SARS-CoV-2 Vaccine in Patients With Hematologic Malignancies
Florent Malard et al., Blood Cancer J, (2021) - CD4+ T Cells of Prostate Cancer Patients Have Decreased Immune Responses to Antigens Derived From SARS-CoV-2 Spike
Pavla Taborska et al., Front Immunol, (2021) - T Cell–Mediated Response to SARS-CoV-2 in Liver Transplant Recipients With Prior COVID-19
Mario Fernández-Ruiz et al., Am J Transplant, (2021) - Prospective Assessment of SARS-CoV-2 Seroconversion (PASS) Study: an Observational Cohort Study of SARS-CoV-2 Infection and Vaccination in Healthcare Workers
Jackson, B.M. et al., BMC Infect Dis, (2021) - Cellular Immunity Predominates Over Humoral Immunity After Homologous and Heterologous mRNA and Vector-Based COVID-19 Vaccine Regimens in Solid Organ Transplant Recipients
Tina Schmidt et al., Am J Translplant, (2021) - The Legacy of Maternal SARS-CoV-2 Infection on the Immunology of the Neonate
Sarah Gee et al., Nat Immunol, (2021) - A Single-Cycle Influenza A Virus-Based SARS-CoV-2 Vaccine Elicits Potent Immune Responses in a Mouse Model
Surapong Koonpaew et al., Vaccines, (2021) - Impact of Multiple Sclerosis Disease-Modifying Therapies on SARS-CoV-2 Vaccine-Induced Antibody and T Cell Immunity
Sabatino, J.J. et al., MedRxiv, (2021) - Complete Protection of Nasal and Lung Airways Against SARS-CoV-2 Challenge by Antibody Plus Th1 Dominant N- and S-Specific T-Cell Responses to Subcutaneous Prime and Thermally-Stable Oral Boost Bivalent hAd5 Vaccination in an NHP Study
Elizabeth Gabitzsch et al., BioRxiv, (2021) - Cytomegalovirus-Specific Immunity Recovers More Slowly after Cord Blood Transplantation Compared with Matched Sibling Donor Allogeneic Transplantation
Bejanyan, J. et al., Transplant Cell Ther, (2021) - The Evaluation of Novel Oral Vaccines Based on Self-Amplifying RNA Lipid Nanparticles (saRNA LNPs), saRNA Transfected Lactobacillus Plantarum LNPs, and saRNA Transfected Lactobacillus Plantarum to Neutralize SARS-CoV-2 Variants Alpha and Delta
Reza Keikha et al., Sci Rep, (2021) - Single-Dose Intranasal Administration of AdCOVID Elicits Systemic and Mucosal Immunity against SARS-CoV-2 and Fully Protects Mice from Lethal Challenge
King R.G. et al., Vaccines, (2021) - T-Cell and Antibody Immunity After COVID-19 mRNA Vaccines in Healthy and Immunocompromised Subjects-An Exploratory Study
Rakesh Sindhi et al., MedRxiv, (2021) - SARS-CoV-2-Specific Antibody and T Cell Response Kinetics According to Symptom Severity
Ji Yeun Kim et al., Am J Trop Med Hyg, (2021) - Implementation of Adenovirus-Mediated Pulmonary Expression of Human ACE2 in HLA Transgenic Mice Enables Establishment of a COVID-19 Murine Model for Assessment of Immune Responses to SARS-CoV-2 Infection
Theodor Chitlaru et al., Pathogens, (2021) - Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 Trial
Punnee Pitisuttihum et al., MedRxiv, (2021) - Protracted yet Coordinated Differentiation of Long-Lived SARS-CoV-2-Specific CD8+ T Cells During COVID-19 Convalescence
Tongcui Ma et al., BioRxiv, (2021) - SARS-Cov-2 Spike Protein Fragment 674–685 Protects Mitochondria From Releasing Cytochrome c in Response to Apoptogenic Influence
Olena Kalashnyk et al., Biochem Biophys Res Commun, (2021) - CD8+PD-L1+CXCR3+ Polyfunctional T Cell Abundances Are Associated With Survival in Critical SARS-CoV-2–Infected Patients
Lucille Adam et al., JCI Insight, (2021) - Protective Antibodies Elicited by SARS-CoV-2 Spike Protein Vaccination are Boosted in the Lung After Challenge in Nonhuman Primates
Joseph R. Francica et al., Sci Transl Med, (2021) - Profiling SARS-CoV-2 HLA-I Peptidome Reveals T Cell Epitopes From Out-of-Frame ORFs
Shira Weingarten-Gabbay et al., Cell, (2021) - A Short Corticosteroid Course Reduces Symptoms and Immunological Alterations Underlying Long-COVID
Alberto Utrero-Rico et al., Biomedicines, (2021) - COVID-19 Vaccine mRNA-1273 Elicits a Protective Immune Profile in Mice That is not Associated With Vaccine-Enhanced Disease Upon SARS-CoV-2 Challenge
DiPiazza, A.T. et al., Immunity, (2021) - Polymeric and Lipid Nanoparticles for Delivery of Self-Amplifying RNA Vaccines
Blakney, A.K. et al., J Control Release, (2021) - An Enveloped Virus-Like Particle Vaccine Expressing a Stabilized Prefusion form of the SARS-CoV-2 spike Protein Elicits Highly Potent Immunity
Anne-Catherine Fluckiger et al., Vaccine, (2021) - Intranasal Plus Subcutaneous Prime Vaccination With a Dual Antigen COVID-19 Vaccine Elicits T-Cell and Antibody Responses in Mice
Adrian Rice et al., Sci Rep, (2021) - Change in Symptoms and Immune Response in People with Post-Acute Sequelae of SARS-Cov-2 Infection (PASC) After SARS-Cov-2 Vaccination
Daisy Massay et al., MedRxiv, (2021) - Evolution of SARS-CoV-2 Immune Responses in Nursing Home Residents Following Full Dose of the Comirnaty® COVID-19 Vaccine
Giménez, E. et al., J Infect (2021) - Correlates of Neutralization against SARS-CoV-2 Variants of Concern by Early Pandemic Sera
Vidal, S-J. et al., J Virol, (2021) - Application of Spectral Library Prediction for Parallel Reaction Monitoring of Viral Peptides
Grossegesse, M. et al., Proteomics, (2021) - Preserved T-cell Response in anti-CD20 Treated Multiple Sclerosis Patients Following SARS-CoV-2 Vaccination
Simon Faissner et al., Res Square, (2021) - Durable T cell responses contrast with faster antibody waning in BNT162b2-vaccinated elderly at 6 month
Laurent Renia et al., Res Square, (2021) - SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responses
Joshua M. Carmen et al., Vaccines, (2021) - mRNA Vaccine Protects against Zika Virus
Lex G. Medina-Magües et al., Vaccines, (2021) - A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates
M. Gordon Joyce et al., Science Translational Medicine - SARS-CoV-2-Specific Cell-Mediated Immunity in Kidney Transplant Recipients Recovered From COVID-19
Mario Fernández-Ruiz et al., Transplantation, (2021) - First-in-Human Phase I Clinical Trial of an SFV-Based RNA Replicon Cancer Vaccine against HPV-Induced Cancers
Fenne L. Komdeur et al., Mol Ther, (2021) - SARS-CoV-2 Vaccination in Rituximab-Treated Patients: B Cells Promote Humoral Immune Responses in the Presence of T-Cell-Mediated Immunity
Daniel Mrak et al., Ann Rheum Dis, (2021) - Comorbid Illnesses are Associated With Altered Adaptive Immune Responses to SARS-CoV-2
Krystle Kq Yu et al., JCI Insight, (2021) - Longitudinal Analysis of Human Memory T-Cell Response According to the Severity of Illness up to 8 Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Chang Kyung Kang et al., J Infect Dis, (2021) - Deconvoluting the T Cell Response to SARS-CoV-2: Specificity Versus Chance and Cognate Cross-Reactivity
Alexander A. Lehmann et al., Front Immunology, (2021) - Identification of Conserved SARS-CoV-2 Spike Epitopes That Expand Public cTfh Clonotypes in Mild COVID-19 Patients
Xiuyuan Lu et al., J Exp Med, (2021) - Cytomegalovirus Specific Polyfunctional T-Cell Responses Expressing CD107a Predict control of CMV Infection After Liver Transplantation
Ângela Carvalho-Gomes et al., Cellular Immunology, (2021) - Off the Shelf Third Party Virus Specific T-Cell Therapy to Treat JC Polyomavirus Infection in Hematopoietic Stem Cell Transplant Recipients
Jeremy D. Rubinstein et al., Transplant Cell Ther, (2021) - Effectiveness of ChAdOx1 nCoV-19 Vaccine Against SARS-CoV-2 Infection During the Delta (B.1.617.2) Variant Surge in India: a Test-Negative, Case-Control Study and a Mechanistic Study of Post-Vaccination Immune Responses
Ramachandran Thiruvengadam et al., Lancet Infect Dis, (2021) - Rituximab impairs B-cell response but not T-cell response to COVID-19 vaccine in auto-immune diseases
Samuel Bitoun et al., Arthritis & Rheumatology, (2021) - Latent CMV Infection Is Associated With Lower Influenza Virus-Specific Memory T-Cell Frequencies, but Not With an Impaired T-Cell Response to Acute Influenza Virus Infection
Sarah P.H. van den Berg et al., Front Immunology, (2021) - Rituximab impairs B-cell response but not T-cell response to COVID-19 vaccine in auto-immune diseases
Samuel Bitoun et al., Arthritis & Rheumatology (2021) - PMID: 34962357 - Latent CMV Infection Is Associated With Lower Influenza Virus-Specific Memory T-Cell Frequencies, but Not With an Impaired T-Cell Response to Acute Influenza Virus Infection
Sara P H van den Berg et al., Front Immunology (2021) - PMID: 34025665
- CMV-Specific Immunity Recovers Slowly after Cord Blood Compared with Matched Sibling Donor Allogeneic Transplantation
N.Bejanyan et.al., Transplantation and Cellular Therapy (2020) - PMID: n.a. - Human Cytomegalovirus-Encoded microRNAs Can Be Found in Saliva Samples from Renal Transplant Recipients
Shelley Waters et.al., Noncoding RNA. (2020) - PMID: 33353107 - Persistent Cellular Immunity to SARS-CoV-2 Infection
Gaëlle Breton et.al., bioRxiv (2020) - PMID: 33330867 - Adaptive Immune Responses to SARS-CoV-2 in Recovered Severe COVID-19 Patients
Beatriz Olea et.al., medRxiv (2020) - PMID: n.a. - 1IL-2 and IFN-γ are Biomarkers of SARS-CoV-2 Specific Cellular Response in Whole Blood Stimulation Assays
Begoña Pérez-Cabezas et.al., medRxiv (2020) - PMID: n.a. - BNT162b2 Induces SARS-CoV-2-Neutralising Antibodies and T Cells in Humans
Ugur Sahin et.al., medRxiv (2020) - PMID: n.a. - Deconvoluting the T Cell Response to SARS-CoV-2: Specificity Versus Chance- and Cognate Cross-Reactivity
Alexander A. Lehmann et.al., bioRxiv (2020) - PMID: n.a. - Guidelines For Analysis of Low-Frequency Antigen-Specific T Cell Results: Dye-Based Proliferation Assay vs 3H-Thymidine Incorporation
Daniela Di Blasi et.al., Journal of Immunological Methods (2020) - PMID: 33152332 - Antigenic Competition in the Generation of Multi-Virus-Specific Cell Lines for Immunotherapy of Human Cytomegalovirus, Polyomavirus BK, Epstein-Barr Virus and Adenovirus Infection in Haematopoietic Stem Cell Transplant Recipients
Kateřina Roubalová et.al., Immunol Lett. (2020) - PMID: 33031870 - Convalescent Plasma Therapy for B-Cell Depleted Patients With Protracted COVID-19 Disease
Thomas Hueso et.al., Blood (2020) - PMID: 32959052 - mRNA Based SARS-CoV-2 Vaccine Candidate CVnCoV Induces High Levels of Virus Neutralizing Antibodies and Mediates Protection in Rodents
Susanne Rauch et.al., bioRxiv (2020) - PMID: n.a. - Functional Immune Monitoring of BK Virus And Donor‐Specific T‐cell Effector Immune Responses to Guide Treatment Decision‐Making After Kidney Transplantation; an Illustrative Case Report And Literature Review
Marta Lepore et.al., Transplant Infectious Disease (2020) - PMID: 33070461 - Divergent SARS‐CoV‐2‐Specific T and B Cell Responses in Severe but Not Mild COVID‐19 Patients
Anna E. Oja et.al., European Journal of Immunology (2020) - PMID: 33073359 - Characteristicsof Rapamycin-Treated T Cell Products for Advanced Adoptive T Cell Therapy and Evaluation of Clinical Feasibility
Leila Amini et.al., Dissertation (2020) - PMID: n.a. - Intrafamilial Exposure to SARS-CoV-2 Induces Cellular Immune Response without Seroconversion
Gallais F. et.al., Emerg Infect Dis (2020) - PMID: n.a. - T Cell and Antibody Responses to SARS-CoV-2: Experience From a French Transplantation and Hemodialysis Center During the COVID-19 Pandemic
Candon S. et.al., Am J Transplant (2020) - PMID: n.a. - Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Evan J. Anderson et.al., New England Journal of Medicine (2020) - PMID: 32991794 - Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques
Mercado et.al., Nature (2020) - PMID: 32731257 - Evaluation of the mRNA-1273 Vaccine Against SARS-CoV-2 in Nonhuman Primates
Corbett et.al., N Engl J Med (2020) - PMID: 32722908 - Divergent SARS-CoV-2-Specific T and B Cell Responses in Severe but not Mild COVID-19
Oja et.al., bioRxiv (2020) - PMID: n.a. - Self-Amplifying RNA SARS-CoV-2 Lipid Nanoparticle Vaccine Candidate Induces High Neutralizing Antibody Titers in Mice
McKay et.al., Nature (2020) - PMID: 32647131 - Generation of SARS-CoV-2 S1 Spike Glycoprotein Putative Antigenic Epitopes in Vitro by Intracellular Aminopeptidases
Stamatakis et.al., bioRxiv (2020) - PMID: n.a. - SARS-CoV-2-Specific T Cells Exhibit Unique Features Characterized by Robust Helper Function, Lack of Terminal Differentiation, and High Proliferative Potential
Neidleman et.al., bioRxiv (2020) - PMID: 32577663 - A Longitudinal Study of Immune Cells in Severe COVID-19 Patients
Payen et.al., medRXiv (2020) - PMID: n.a. - SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness
Corbett et.al., bioRxiv (2020) - PMID: 32577634 - Presence of SARS-CoV-2 Reactive T Cells in COVID-19 Patients and Healthy Donors
Braun et.al., Nature (2020) - PMID: 32726801 - SARS‐CoV‐2‐Reactive Interferon‐γ‐Producing CD8+ T Cells in Patients Hospitalized with Coronavirus Disease 2019
Estela Giménez et.al., Journal of Medical Virology (2020) - PMID: 32579268 - Evaluation of T-Activated Proteins as Recall Antigens to Monitor Epstein–Barr Virus and Human Cytomegalovirus-Specific T Cells in a Clinical Trial Setting
Nina Körber et.al., Journal of Translational Medicine (2020) - PMID: 32552697 - Modified Alphavirus-Vesiculovirus Hybrid VaccineVectors for Homologous Prime-Boost Immunotherapyof Chronic Hepatitis B
Carolina Chiale et.al., Vaccines (2020) - PMID: 32517032 - Duration of Cellular and Humoral Responses After Quadrivalent Human Papillomavirus Vaccination in Healthy Female Adultswith or Without Prior Type 16 and/or 18 Exposure
Lilin Lai et.al., Vaccines (2020) - PMID: n.a. - A SARS-CoV-2 mRNA Vaccine — Preliminary Report
Lisa A Jackson et.al., N Engl J Med (2020) - PMID: 32663912 - HBV‐Specific CD8 T Cells Present Higher TNFα Expression But Lower Cytotoxicity in Hepatocellular Carcinoma
Ludong Zhao et.al., Clinical & Experimental Immunology (2020) - PMID: 32474905 - Safety and Immunogenicity of a Zika Purified Inactivated Virus Vaccine Given Via Standard, Accelerated, or Shortened Schedules: a Single-Centre, Double-Blind, Sequential-Group, Randomised, Placebo-Controlled, Phase 1 Trial
Kathryn E Stephenson et.al., The Lancet Infectious Diseases (2020) - PMID: n.a. - Assessing Anti-HCMV Cell Mediated Immune Responses in Transplant Recipients and Healthy Controls Using a Novel Functional Assay
Charlotte J. Houldcroft et.al., Cell-Mediated Immunity to HCMV (2020) - PMID: n.a. - Evaluation of Glycoprotein E Subunit And Live Attenuatedvaricella‐Zoster Virus Vaccines Formulated With Asingle‐Strand RNA‐Based Adjuvant
Su Jeen Lee et.al., Immunity, Inflammation and Disease (2020) - PMID: 32167678 - Women Who Received Varicella Vaccine Versus Natural Infection Have Different Long-Term T Cell Immunity but Similar Antibody Levels
Ellen Tourtelot et.al., Vaccine (2020) - PMID: 31959424 - TGF‐β Promotes The Function Of HIV‐Specific CXCR5+CD8 T Cells
Hong-Ge Yang et.al., Microbiology and Immunology (2020) - PMID: 32221997 - Persistent Expansion And Th1-Like Skewing of HIV-Specific Circulating T Follicular Helper Cells During Antiretroviral Therapy
Julia Niessl Wu et.al., EBioMedicine (2020) - PMID: 32268275 - Preserved Specific Anti-Viral T-Cell Response But Associated With Decreased Lupus Activity In SLE Patients With Cytomegalovirus Infection
Chien-Sheng Wu et.al., British Society for Rheumatology (2020) - PMID: 32306043 - A Chimeric Yellow Fever-Zika Virus Vaccinecandidate Fully Protects Against Yellow Fever Virusinfection in Mice
Dieudonné Buh Kum et.al., Emerging Microbes & Infections (2020) - PMID: 32116148 - Efficacy, Immunogenicity, and Safety of an Oral Influenza Vaccine: a Placebo-Controlled And Active-Controlled Phase 2 Human Challenge Study
David Liebowitz et.al., The Lancet Infectious Diseases (2020) - PMID: 31978354 - Immunogenicity of Novel mRNA COVID-19 Vaccine MRT5500 in Mice and 2 Non-Human Primates
Kirill V. Kalnin et.al., Cancer Discovery (2019) - PMID: n.a. - Tracking Dye‐Independent Approach to Identify and Isolate In Vitro Expanded T Cells
George Elias et.al., Journal of Quantitative Cell Science (2019) - PMID: 31356002 - Adenovirus Vector-Based Vaccines Confer Maternal-Fetal Protection against Zika Virus Challenge in Pregnant IFN-αβR−/− Mice
Rafael A.Larocca et.al., Clinical and Translational Report (2019) - PMID: 31668877 - Tumor-Infiltrating B Cells Affect the Progression of Oropharyngeal Squamous Cell Carcinoma Via Cell-To-Cell Interactions With CD8+ T Cells
Kamila Hladikova et.al., Journal for ImmunoTherapy of Cancer (2019) - PMID: 31623665 - PD-1 Blockade and TLR7 Activationlack Therapeutic Benefit in Chronic SIV-Infected Macaqueson Antiretroviral Therapy
Elena Bekerman et.al., Antimicrob. Agents Chemother. (2019) - PMID: 31501143 - Deciphering Effects of Uncontrolled Cytomegalovirus Replication on Immune Responses in Cytomegalovirus DNA-Positive Renal Transplant Recipients
Nandini Makwana et.al., Viral Immunology (2019) - PMID: 31536468 - Generation of HPV-Specific T-Cells
Carlos A. Ramos et.al., United States Patent Application 20190224302 (2019) - PMID: n.a. - A Vaccine Based on Recombinant Modified Vaccinia Ankara Containing the Nucleoprotein from Lassa Virus Protects Against Disease Progression in a Guinea Pig Model
E.M.Kennedy et.al., Vaccine (2019) - PMID: 31331770 - A Novel Simplified Method of Generating Cytomegalovirus-Specific Cytokine-Induced Killer Cells of High Specificity and Superior Potency with GMP Compliance
Yen Hoon Luah et.al., Clinical Immunology (2019) - PMID: 31229666 - Generation of Zika Virus–Specific T Cells from Seropositive and Virus-Naïve Donors for Potential Use as an Autologous or “Off-the-Shelf” Immunotherapeutic
Ryo Hanajiri et.al., Cytotherapy (2019) - PMID: n.a. - HBeAg Seroconversion is Associated with a More Effective PD-L1 Blockade During Chronic Hepatitis B Infection
Sara Ferrando-Martinez et.al., JHEP Reports (2019) - PMID: n.a. - Enhancement of Immune Responses by Guanosine-Based Particles in DNA Plasmid Formulations against Infectious Diseases
Saritza Santos et.al., Journal of Immunology Research (2019) - PMID: n.a. - Prospective Assessment of CMV Immunity in High-Risk Donor Seropositive (D+) Recipient Seronegative (R-) Liver Transplant Recipients Receiving Either Preemptive Therapy or Prophylaxis
Ajit P Limaye et.al. ,The Journal of Infectious Diseases (2019) - PMID: n.a. - Phenotypic and Functional Differences Between HHV-6 and HCMV Specific T-Cells
Solène Fastenackels et.al. , Journal of Virology (2019) - PMID: 30996090 - Evaluation of EBV- and HCMV-Specific T Cell Responses in Systemic Lupus Erythematosus (SLE) Patients Using a Normalized Enzyme-Linked Immunospot (ELISPOT) Assay
Irene Cassaniti et.al. , PLoS Pathogens (2019) - PMID: n.a. - T-Cell Responses Targeting HIV Nef Uniquely Correlate With Infected Cell Frequencies After Long-Term Antiretroviral Therapy
Allison S. Thomas et.al. , PLoS Pathogens (2019) - PMID: 28931091 - Measurement of CD8.sup.+ and CD4.sup.+ T Cell Frequencies Specific for EBV LMP1 and LMP2a Using mRNA-Transfected DCs
Dae-Hee Sohn et.al. , PLoS ONE (2019) - PMID: 26023769 - Efficient Induction of Cell-Mediated Immunity to Varicella-Zoster Virus Glycoprotein E Co-Lyophilized with a Cationic Liposome-Based Adjuvant in Mice
Seo Ri Wui et.al. , Vaccine (2019) - PMID: 30827737 - Penalized Supervised Star Plots: Example Application in Influenza-Specific CD4+ T Cells
Tyson H. Holmes et.al. , Viral Immunology (2019) - PMID: 30698511 - Antigen-Specific TCR Signatures of Cytomegalovirus Infection
Alina Huth et.al. , The Journal of Immunology (2018) - PMID: 30587531 - Developmental Induction of Human T-cell Responses Against Candida Albicans and Aspergillus Fumigatus
Katrin Vogel et.al. , Scientific Reportsvolume (2018) - PMID: 30442915 - Activation of Resident Memory T Cells for Cancer Immunotherapy
Masopust Jr et.al. , United States Patent Application 20180325952 (2018) - PMID: n.a. - Epstein-Barr Virus (EBV)-derived BARF1 Encodes CD4-and CD8-restricted Epitopes as Targets for T-cell Immunotherapy
M Kalra et.al. , Cytotherapy (2018) - PMID: 30396848 - Generating HPV Antigen-specific Cells from a Native T Cell Population
CM Bollard et.al. , US Patent App. 15/771,648, 2018 (2018) - PMID: n.a. - Method For Preparing Genetically-Modified T Cells Which Express Chimeric Antigen Receptor
Nishio et.al. , United States Patent Application 20180289742 (2018) - PMID: n.a. - PI Highlight
LL Kelley , PACT Newsletter (2018) - PMID: n.a. - Replication Deficient Human Adenovirus Vector Serotype 19a/64: Immunogenicity in Mice and Female Cynomolgus Macaques
Ragonnaud et al., Vaccine (2018) - PMID: 30190120 - Establishment and Operation of a Third Party Virus-Specific T-Cell Bank Within an Allogeneic Stem Cell Transplant Program
Withers et al., Biology of Blood and Marrow Transplantation (2018) - PMID: 30172015 - Humoral and Cellular Immunity to RSV in Infants, Children and Adults
Green et al., Vaccine (2018) - PMID: 30177258 - Altered CD4+ T‐Cell Immunity in Nurses Occupationally Exposed to Viral Pathogens
Elias et al., Clin Exp Immunol (2018) - PMID: 30076783 - Dynamics of Virus‐Specific T Cell Immunity in Pediatric Liver Transplant Recipients
Arasaratnam et al., American Journal of Transplantation (2018) - PMID: 29900673 - Pepmixes To Generate Multiviral Ctls With Broad Specificity
Leen et al., US Patent App. 15/905,176, (2018) - PMID: n.a. - Deleterious Effect of Steroids on Cytomegalovirus Infection Rate after Allogeneic Stem Cell Transplantation Depends on Pretransplant Cytomegalovirus Serostatus of Donors and Recipients
Suárez-Lledó et al., Biology of Blood and Marrow Transplantation (2018) - PMID: 29753162 - Antiviral T Cells for Adenovirus in the Pretransplant Period: A Bridge Therapy for Severe Combined Immunodeficiency
Miller et al., Biology of Blood and Marrow Transplantation (2018) - PMID: 29753156 - Employment of the Human Thymus as an Alternative Source of Regulatory T-Cells to Develop an Immunotherapy to Prevent Rejection in Transplanted Children
Bernaldo de Quirós et al., Cytotherapy (2018) - PMID: n.a. - Production of Quadrivalent Virus-Specific T Cells Utilizing Peptide Stimulation
A. Damen et al., Cytotherapy (2018) - PMID: n.a. - An Antigen-Free, Plasmacytoid Dendritic Cell–Targeting Immunotherapy To Bolster Memory CD8+ T Cells in Nonhuman Primates
Masuta et al., J Immunol. (2018) - PMID: 29431693 - Multi-Antigenic Human Cytomegalovirus mRNA Vaccines that Elicit Potent Humoral and Cell-Mediated Immunity
John et al., Sci Rep. (2018) - PMID: 29456015 - Cytomegalovirus-Specific T-Cells Are Associated with Immune Senescence, But Not With Systemic Inflammation, in People Living with HIV
Ballegaard et al., Sci Rep. (2018) - PMID: 29491459 - Toward a Rapid Production of Multivirus-Specific T Cells Targeting BKV, Adenovirus, CMV, and EBV from Umbilical Cord Blood
Corrales et al., Mol Ther Methods Clin Dev. (2017) - PMID: 28480300 - IL28B Genetic Variation and Cytomegalovirus-Specific T-cell Immunity in Allogeneic Stem Cell Transplant Recipients.
Corrales et al., Journal of Medical Virology (2015) - PMID: 27591738 - Mycobacteria-Specific Cytokine Responses Detect TB Infection and Distinguish Latent from Active TB
Tebruegge et al., Am J Respir Crit Care Med. (2015) - PMID: 26030187 - Method for Preparing Antigen-Specific Cytotoxic T-Cells by Using Activated B-Cells and use Thereof
Kang et al., United States Patent Application 20180023054 (2018) - PMID: n.a. - Production of Trivalent Antigen-Specific T Cells Utilizing Viral Peptide Stimulation
Heyenbruch et al., Biology of Blood and Marrow Transplantation (2018) - PMID: n.a. - Differential Expression of CD8+ T Cell Cytotoxic Effector Molecules in Blood and Gastrointestinal Mucosa in HIV-1 Infection
Kiniry et al., The Journal of Immunology (2018) - PMID: 29352005 - "Cytomegalovirus (CMV) Immune Monitoring with ELISPOT and QuantiFERON-CMV Assay in Seropositive Kidney Transplant Recipients"
Lee et al., Plos One (2017) - PMID: 29232714 - Asian Elephant T Cell Responses to Elephant Endotheliotropic Herpesvirus (EEHV)
Fuery et al., Journal of Virology (2017) - PMID: 29263271 - Follistatin-Like Protein-1 Upregulates Dendritic Cell-Based Immunity in Patients with Nasopharyngeal Carcinoma
Wang Hong et al., Journal of Interferon & Cytokine Research (2017) - PMID: 29135371 - Methods of Cell Culture for Adoptive Cell Therapy
Vera et al., US Patent 20,170,267,973, 2017 (2017) - PMID: n.a. - The Effect of Genetic Variants Affecting NK Cell Function on Cardiovascular Health and the Burden on CMV
Waters et al., Hum Immunol. (2017) - PMID: 28987961 - Protein Structure Shapes Immunodominance in the CD4 T cell Response to Yellow Fever Vaccination
Koblischke et al., Sci Rep. (2017) - PMID: 28827760 - Immunologic Profiling of Human Metapneumovirus (hMPV) Towards the Development of a Targeted Immunotherapy
Tzannou et al., The Journal of Infectious Diseases (2017) - PMID: n.a - Safety and Immunogenicity of a mRNA Rabies Vaccine in Healthy Adults: an Open-label, Non-randomised, Prospective, First-in-human Phase 1 Clinical Trial
Alberer et al., Lancet. (2017) - PMID: 28754494 - Vorinostat Renders the Replication-Competent Latent Reservoir of Human Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8 T Cells
Sung et al., EBioMedicine (2017) - PMID: 28803740 - CpG Oligonucleotides Increase HBV-Specific Cytokine Responses in Whole Blood and Enhance Cytokine Release Assay Sensitivity
Dammermann et al., J Virol Methods (2017) - PMID: 28739303 - Elucidating CD8+ T-Cell Responses in the Rectal Mucosa During HIV Infection
Kiniry et al., ProQuest (2017) - PMID: n.a. - Vaccination with a Codon-Optimized A27L-Containing Plasmid Decreases Virus Replication and Dissemination After Vaccinia Virus Challenge
Martínez et al., Vaccine (2017) - PMID: 28629922 - Pre-Transplant Immune Factors May be Associated with BK Polyomavirus Reactivation in Kidney Transplant Recipients
DeWolfe et al., Plos one (2017) - PMID: 28562595 - Decitabine Treatment Sensitizes Tumor Cells to T-Cell-Mediated Cytotoxicity in Patients with Myelodysplastic Syndromes
Zheng Zhang et al., Am J Transl Res (2017) - PMID: 28337274 - An Early Immediate Early Protein IE-1–Specific T-Cell Polyfunctionality Is Associated With a Better Control of Cytomegalovirus Reactivation in Kidney Transplantation
Dekeyser et al., Kidney International Reports (2017) - PMID: n.a. - Development of a Replication-Deficient Adenoviral Vector-Based Vaccine Candidate for the Interception of HPV16- and HPV18-Induced Infections and Disease
Khan et al., International Jounal of Cancer (2017) - PMID: 28263390 - Breadth of T Cell Responses after Immunization with Adenovirus Vectors Encoding Ancestral Antigens or Polyvalent Papillomavirus Antigens
Ragonnaud et al., Scandinavian Journal of Immunology (2017) - PMID: 28109028 - Primary Cytomegalovirus Infection in Seronegative Kidney Transplant Patients Is Associated with Protracted Cold Ischemic Time of Seropositive Donor Organs
Schlott et al., Plos One (2017) - PMID: 28129395 - Perturbed CD8+ T Cell TIGIT/CD226/PVR Axis Despite Early Initiation of Antiretroviral Treatment in HIV Infected Individuals
Tauriainen et al., Scientific Reports (2017) - PMID: 28084312 - Development of Novel Replication-defective Lymphocytic Choriomeningitis Virus Vectors Expressing SIV Antigens
MacMaster et al., Vaccine (2016) - PMID: 27899229 - T Cells Infiltrating Diseased Liver Express Ligands for the NKG2D Stress Surveillance System
Huang et al., Journal of Immunology (2016) - PMID: 28031333 - Polynucleotides For Treating Oncogenic Viral Polypeptide Positive Tumors
Lee et al., US Patent 20,160,376,324 (2016) - PMID: n.a. - Therapeutic Vaccine Targeting Epstein-Barr Virus Latent Protein, LMP1, Suppresses LMP1-Expressing Tumor Growth and Metastasis in Vivo
Lin et al., BMC Cancer (2016) - PMID: 28056887 - Immune Monitoring to Predict and Prevent Infection
Palmer et al., US Patent 20,160,377,602, 2016 (2016) - PMID: na. - Predominance of Weakly Cytotoxic, T-betLowEomesNeg CD8+ T-Cells in Human Gastrointestinal Mucosa: Implications for HIV Infection.
Kiniry et al., Mucosal Immunology (2016) - PMID: 27827375 - Expression of DAI by an Oncolytic Vaccinia Virus Boosts the Immunogenicity of the Virus and Enhances Antitumor Immunity
Hirvinen et al., Molecular Therapy (2016) - PMID: 27626058 - αβ T Cell Receptor Germline CDR Regions Moderate Contact with MHC Ligands and Regulate Peptide Cross-Reactivity
Attaf et al., Scientific Reports (2016) - PMID: 27775030 - Mapping the Sequence Space of ZIKA and Related Viruses: High-Content Peptide Libraries for Immune Monitoring
von Hoegen et al., (2016) - PMID: n.a. - The Challenge of Complexity: Peptide Tools for the Development of Immunotherapies
Schnatbaum et al., (2016) - PMID: n.a. - Circulating Functional T Cells Specific to HHV6 Antigens in Individuals With Chromosomally Integrated HHV-6 (ciHHV6)
Barozzi et al., Clinical Microbiology and Infection (2016) - PMID: 27404369 - Human Papillomavirus 16 (HPV16) and HPV52 E6-Specific Immunity in HIV-Infected Adults on Combination Antiretroviral Therapy
Leng et al., HIV Medicine (2016) - PMID: 27649852 - Immune Responses Elicited by the GEN-003 Candidate HSV-2 Therapeutic Vaccine in a Randomized Controlled Dose-Ranging Phase 1/2a Trial
Flechtner et al., Vaccine (2016) - PMID: 27642130 - Functional Diversity of CMV-Specific T-Cells is Maintained in Older People and Significantly Associated with Protein Specificity and Response Size
Bajwa et al., The Journal of Infetious Diseases (2016) - PMID: 27521364 - Self-Amplifying mRNA Vaccines Expressing Multiple Conserved Influenza Antigens Confer Protection against Homologous and Heterosubtypic Viral Challenge
Magini et al., PloS one (2016) - PMID: 27525409 - Increased Frequency of BK Virus-Specific Polyfunctional CD8+ T Cells Predict Successful Control of BK Viremia After Kidney Transplantation
Schaenman et al., Transplantation (2016) - PMID: 27391197 - Protective Efficacy of Multiple Vaccine Platforms Against Zika Virus Challenge in Rhesus Monkeys
Abbink et al., Science (2016) - PMID: 27492477 - Distinct Metabolic Requirements of Exhausted and Functional Virus-Specific CD8 T Cells in the Same Host
Schurich et al., Cell reports (2016) - PMID: 27452473 - Complementary Effects of IL-15 and IFN-α Induce Immunity in HBV Transgenic Mice
Di Scala et al., Journal of virology (2016) - PMID: 27440883 - Composition and Dynamics of the Uterine NK Cell KIR Repertoire in Menstrual Blood
Ivarsson et al., Mucosal Immunol. (2016) - PMID: 27271316 - Validation of an IFNγ/IL2 FluoroSpot Assay for Clinical Trial Monitoring
Körber et al., J Transl Med. (2016) - PMID: 27297580 - A Single Exercise Bout Enhances the Manufacture of Viral-Specific T-cells from Healthy Donors: Implications for Allogeneic Adoptive Transfer Immunotherapy
Spielmann et al., Sci Rep (2016) - PMID: 27181409 - Cellular Interferon Gamma and Granzyme B Responses to Cytomegalovirus-pp65 and Influenza N1 Are Positively Associated in Elderly
Theeten et al., Viral Immunology (2016) - PMID: 27002465 - Reconstitution of Cytomegalovirus-Specific T-Cell Response in Allogeneic Hematopoietic Stem Cell Recipients: the Contribution of Six Frequently Recognized, Virus-Encoded ORFs
Nemeckova et al., Transpl Infect Dis. (2016) - PMID: 27061389 - The VZV/IE63-Specific T Cell Response Prevents Herpes Zoster in Fingolimod-Treated Patients
Mathias et al., Neurology (2016) - PMID: n.a. - Cytotoxic Polyfunctionality Maturation of Cytomegalovirus-pp65-specific CD4+ and CD8+ T-cell Responses in Older Adults Positively Correlates with Response Size
Chiu et al., Sci Rep. (2016) - PMID: 26778409 - Restoring Tissue-Like Functionality in Circulating CD8 T-Cells: Mechanistic Studies and Application in Immunomonitoring of Cancer Patients
Wegner et al., Thesis for a doctoral degree at the Graduate School of Life Sciences, University Würzburg, Germany (2016) - PMID: n.a. - In Vitro Studies of the Impact of Maribavir on CMV-Specific Cellular Immune Responses
Stachel et al., J Clin Virol. (2015) - PMID: 26780109 - Generation of Broadly-Specific, Virus-Immune Cells Targeting Multiple HIV Antigens For Prenventive and Therapeutic Use
Bollard et al., US Patent 20,150,359,876 (2015) - PMID: n.a. - Recombinant Particle Based Vaccines Against Human Cytomegalovirus Infection
Wellnitz et al., US Patent 20,150,359,879 (2015) - PMID: n.a. - Induction Of Broad-Based Immunity and Protective Efficacy by Self-Amplifying mRNA Vaccines Encoding Influenza Virus Hemagglutinin
Brazzoli et al., Journal of Virology (2015) - PMID: 26468547 - Functionally Active HIV-Specific T Cells that Target gag and nef Can Be Expanded from Virus-Naive Donors and Target a Range of Viral Epitopes: Implications for a Cure Strategy after Allogeneic HSCT
Patel et al., Biology of Blood and Marrow Transplantation (2015) - PMID: n.a. - Characteristics of Immune Memory 10–15 years After Primary Hepatitis B Vaccination
Hummel et al., Vaccine (2015) - PMID: n.a. - IL-12–Dependent Cytomegalovirus-Specific CD4+ T Cell Proliferation, T-bet Induction, and Effector Multifunction during Primary Infection Are Key Determinants for Early Immune Control
Popescu et al., J Immunol. (2015) - PMID: 26663780 - Safety of Human Immunisation With a Live-attenuated Mycobacterium Tuberculosis Vaccine: a Randomised, Double-blind, Controlled Phase I Trial
Spertini et al., The Lancet Respiratory Medicine (2015) - PMID: n.a - Luciferase mRNA Transfection of Antigen Presenting Cells Permits Sensitive Non-radioactive Measurement of Cellular and Humoral Cytotoxicity
Omokoko et al., Journal of Immunology Research (2015) - PMID: n.a. - A Novel Lipid Nanoparticle Adjuvant Significantly Enhances B Cell and T Cell Responses to Sub-unit Vaccine Antigens
Swaminathan et al., Vaccine (2015) - PMID: 26555351 - Peptide Libraries for the Comprehensive Coverage of the Tumor Mutanome for Immune Monitoring and Immuno Therapy
von Hoegen et al., Journal for ImmunoTherapy of Cancer (2015)- PMID: n.a. - Prognostic Impact of Circulating Her-2-reactive T-cells Producing Pro- and/or anti-inflammatory Cytokines in Elderly Breast Cancer Patients
Bailur et al., J Immunother Cancer. (2015) - PMID: 26500775 - Targeting of Nucleoprotein to Chemokine Receptors by DNA Vaccination Results in Increased CD8+-mediated Cross Protection Against Influenza
Baranowska et al., Vaccine (2015) - PMID: 26387432 - An Immunoinformatic Approach for Identification of Trypanosoma cruzi HLA-A2-Restricted CD8+ T cell Epitopes
Eickhoff et al., Hum Vaccin Immunother. (2015) - PMID: 26107442 - Innate Immune Activity Correlates with CD4 T Cell-associated HIV-1 DNA Decline During Latency-Reversing Treatment with Panobinostat
Olesen et al., Journal of Virology (2015) - PMID: 26223643 - Chimpanzee Adenovirus– and MVA-Vectored Respiratory Syncytial Virus Vaccine is Safe and Immunogenic in Adults
Green et al., Science Translational Medicine. (2015) - PMID: n.a - Efficacy of a Virus-Vectored Vaccine Against Human and Bovine Respiratory Syncytial Virus Infections
Taylor et al., Science Translational Medicine. (2015) - PMID: n.a - Immune Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation and Association With Occurrence and Outcome of Invasive Aspergillosis
Stuehler et al., The Journal of Infectious Disease. (2015) - PMID: 25748323 - CD4+CD28null T Lymphocytes Resemble CD8+CD28null T Lymphocytes in Their Responses to IL-15 and IL-21 in HIV-infected Patients
Echeverría et al., J. Leukoc. Biol. (2015) - PMID: 26034206 - Epstein-Barr Virus Reactivation Does Not Impact Total T-Cell Reconstitution But Is Associated With Decreased Functional T Cells after Stem Cell Transplantation
Pietersma et al., J Clin Cell Immunol (2015) - PMID: n.a - T Cells Specific for Different Latent and Lytic Viral Proteins Efficiently Control Epstein-Barr Virus–Transformed B Cells
Nowakowska et al., Cytotherapy (2015) - PMID: 26276009 - Methods of Cell Culture for Adoptive Cell Therapy
Vera et al., US Patent 20,150,175,966, 2015 - PMID: n.a - High-Density Preculture of PBMCs Restores Defective Sensitivity of Circulating CD8 T Cells to Virus- and Tumor-derived Antigens
Wegner et al., Blood (2015) - PMID: 26024876 - Metabolic Regulation of Hepatitis B Immunopathology by Myeloid-derived Suppressor Cells
Pallett et al., Nature Medicine (2015) - PMID: 25962123 - ABO‐Desensitization Affects Cellular Immunity and Infection Control after Renal Transplantation
Schachtner et al., Transplant International (2015) - PMID: 26033637 - The Tuberculosis Vaccine H4: IC31 is Safe and Induces a Persistent Polyfunctional CD4 T cell Response in South African Adults: A Randomized Controlled Trial
Geldenhuys et al., Vaccine (2015) - PMID: 26048780 - Priming with a Simplified Intradermal HIV-1 DNA Vaccine Regimen followed by Boosting with Recombinant HIV-1 MVA Vaccine Is Safe and Immunogenic: A Phase Iia Randomized Clinical Trial
Munseri et al., PloSOne (2015) - PMID: 25875843 - Comparing Humoral and Cellular Immune Response Against HBV Vaccine in Kidney Transplant Patients
Friedrich et al., Am J Transplant. (2015) - PMID: 26137874 - Guidelines For the Automated Evaluation of Elispot Assays
Janetzki et al., Nature Protocols (2015) - PMID: 26110715 - Peripheral Blood–Derived Virus-Specific Memory Stem T Cells Mature to Functional Effector Memory Subsets with Self-Renewal Potency
Schmueck-Henneresse, The Journal of Immunology (2015) - PMID: 25917088 - A Comparative Phase 1 Clinical Trial to Identify Anti-infective Mechanisms of Vitamin D in People With HIV Infection
Lachmann et al., AIDS (2015) - PMID: 25870995 - HCV-Specific Lymphocyte Responses in Individuals with Positive Anti-HCV but Negative HCV-RNA
Sili et al., Journal of Clinical Virology (2015) - PMID: n.a. - Safety and Immunogenicity of a Modified Vaccinia Ankara-based HIV-1 Vaccine (MVA-B) in HIV-1-Infected Patients Alone or in Combination with a Drug to Reactivate latent HIV-1
Mothe et al., J Antimicrob Chemother. (2015) - PMID: 25724985 - A Single Bout of Dynamic Exercise by Healthy Adults Enhances the Generation of Monocyte-Derived-Dendritic Cells
LaVoy et al., Cellular Immunology (2015) - PMID: n.a. - Discordant Humoral and Cellular Immune Responses to Cytomegalovirus (CMV) in Glioblastoma Patients Whose Tumors are Positive for CMV
Rahbar et al., OncoImmunology (2015) - PMID: n.a. - Early Transduction Produces Highly Functional Chimeric Antigen Receptor-modified Virus-specific T-cells with Central Memory Markers: a Production Assistant for Cell Therapy (PACT) Translational Application
Sun et al., J Immunother Cancer. (2015) - PMID: 25734008 - Role of Naïve-Derived T Memory Stem Cells in T Cell Reconstitution Following Allogeneic Transplantation
Roberto et al., Blood. (2015) - PMID: 25742699 - Multispecific Aspergillus T Cells Selected by CD137 or CD154 Induce Protective Immune Responses Against the Most Relevant Mold Infections
Stuehler et al., The Journal of Infectious Disease (2015) - PMID: 25367298 - Mycobacterium Tuberculosis-Specific and MHC Class I-Restricted CD8+ T-Cells Exhibit a Stem Cell Precursor-Like Phenotype in Patients with Active Pulmonary Tuberculosis
Axelsson-Robertson et al., Int J Infect Dis. (2015) - PMID: 25809750 - The Loss of BKV-Specific Immunity From Pretransplantation to Posttransplantation Identifies Kidney Transplant Recipients at Increased Risk of BKV Replication
Schachtner et al., Am J Transplant. (2015) - PMID: 25808077 - Diagnostics Reagents
Jones et al., US Patent 20,150,093,766 (2015) - PMID: n.a. - CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells
Wang et al., Clin Cancer Res. (2015) - PMID: 25838392 - Selection of Adenovirus-specific and Epstein-Barr virus–specific T Cells With Major Histocompatibility Class I Streptamers Under Good Manufacturing Practice (GMP)–Compliant Conditions
Freimüller et al., Cytotherapy (2015) - PMID: 25866178 - Cutting Edge: Identification and Characterization of Human Intrahepatic CD49a+ NK Cells
Marquardt et al., J Immunol. (2015) - PMID: 25672754 - Potential role of CC Chemokine Receptor 6 (CCR6) in Prediction of Late‐onset CMV Infection Following Solid Organ Transplant
Camargo et al., Clin Transplant. (2015) - PMID: 25690781 - Polynucleotides for Treating Oncogenic Viral polypeptide Positive Tumors
Lee et al., US Patent 20,150,023,996, (2015) - PMID: n.a. - Functional Exhaustion limits CD4+ and CD8+ T Cell Responses to Congenital Cytomegalovirus Infection
Huygens et al., J Infect Dis. (2015) - PMID: 25657256 - Early Exposure to Interleukin-21 Limits Rapidly Generated Anti–Epstein-Barr Virus T-cell Line Differentiation
Orio et al., Cytotherapy. (2015) - PMID: 25661862 - STAT3 Signaling Contributes to the High Effector Activities of Interleukin-15-derived Dendritic Cells
Okada et al., Immunol Cell Biol. (2015) - PMID: 25582338 - Human Papillomavirus 16-Specific T-Cell Responses and Spontaneous Regression of Anal High-Grade Squamous Intraepithelial Lesions
Tong et al., J Infect Dis. (2015) - PMID: 25139018 - Intracellular Cytokine Staining on PBMCs Using CyTOFTM Mass Cytometry
Lin et al., bio-protocol.org - PMID: n.a. - The External Quality Assurance Oversight Laboratory (EQAPOL) Proficiency Program for IFN-gamma Enzyme-Linked ImmunoSpot (IFN-γ ELISpot) Assay
Sanchez et al., J Immunol Methods. (2014) - PMID: n.a. - Establishment and Maintenance of a PBMC Repository for Functional Cellular Studies in Support of Clinical Vaccine Trials
Sambor et al., J Immunol Methods. (2014) - PMID: 24787274 - CMV Specific Cytokine Release Assay in Whole Blood is Optimized by Combining Synthetic CMV Peptides and Toll Like Receptor Agonists
Dammermann et al., Journal of Immunological Methods (2014) - PMID: n.a. - Naïve and Memory CD8 T Cell Pool Homeostasis in Advanced Aging: Impact of Age and of Antigen-specificRresponses to Cytomegalovirus
Vescovini et al., Age (Dordr). (2014) - PMID: 24318918 - Preformed Frequencies of Cytomegalovirus (CMV)–Specific Memory T and B Cells Identify Protected CMV-Sensitized Individuals Among Seronegative Kidney Transplant Recipients
Lúcia et al., Clinical Infectious Diseases (2014) - PMID: 25048845 - A Recombinant Modified Vaccinia Ankara Vaccine Encoding Epstein–Barr Virus (EBV) Target Antigens: A Phase I Trial in UK Patients with EBV-Positive Cancer
Taylor et al., Clin. Cancer Res. (2014) - PMID: 25124688 - Human B Cells Produce Chemokine CXCL10 in the Presence of Mycobacterium Tuberculosis Specific T Cells
Hoff et al., Tuberculosis (2014) - PMID: n.a. - Expression of the Human Cytomegalovirus UL11 Glycoprotein in Viral Infection and Evaluation of its Effect on Virus-Specific CD8 T Cells
Gabaev et al., Journal of Virology (2014) - PMID: 25275132 - HPV16-Specific T-Cell Responses and Spontaneous Regression of Anal High-Grade Squamous Intraepithelial Lesions
Tong et al., J Infect Dis. (2014) - PMID: 25139018 - Immune Responses Againgst Mycobacterium Tuberculosis Targets Associated to Latent and Active Tuberculosis Infection
Montserrat Alvarez-Corrales, Published by Karolinska Institutet (2014) - PMID: n.a. - Preferential Infection of Human Ad5-Specific CD4 T Cells by HIV in Ad5 Naturally Exposed and Recombinant Ad5-HIV Vaccinated Individuals
Hu et al., PNAS (2014) - PMID: 25197078 - Diminished Humoral Responses Against and Reduced Gene Expression Levels of Human Endogenous Retrovirus-K (HERV-K) in Psoriasis
Gupta et al., Journal of Translational Medicine (2014) - PMID: 25224121 - Gene Therapy for Rhesus Monkeys Heterozygous for LDL Receptor Deficiency by Balloon Catheter Hepatic Delivery of Helper-Dependent Adenoviral Vector
Oka et al., Gene Therapy (2014) - PMID: 25231173 - Superior In Vitro Stimulation of Human CD8+ T-Cells by Whole Virus versus Split Virus Influenza Vaccines
Halbroth et al., PLoS One (2014) - PMID: PLoS One (2014) - Activity of Broad-Spectrum T Cells as Treatment for AdV, EBV, CMV, BKV, and HHV6 Infections After HSCT
Papadopoulou et al., Sci Transl Med. (2014) - PMID: 24964991 - Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
Fourati et al., JoVE (2014) - PMID: 25046399 - The Role of CD4+ T Cells in BKV-Specific T Cell Immunity
Weist et al., Med Microbiol Immunol. (2014) - PMID: 25052009 - NetFCM: A Semi-Automated Web-Based Method for Flow Cytometry Data Analysis
Frederiksen et al., Cytometry A. (2014) - PMID: 25044796 - T-Bet and Eomes Are Differentially Linked to the Exhausted Phenotype of CD8+ T Cells in HIV Infection
Buggert et al., PLoS Pathog. (2014) - PMID: 25032686 - Specificities of Human CD4+ T Cell Responses to an Inactivated Flavivirus Vaccine and Infection: Correlation with Structure and Epitope Prediction
Schwaiger et al., J Virol. (2014) - PMID: 24789782 - Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19-IL2 Results in Sustained Clinical and Systemic Immunological Responses
Weide et al., American Association for Cancer Research (2014) - PMID: n.a - BK Polyomavirus‐Specific Cellular Immune Responses Are Age‐Dependent and Strongly Correlate With Phases of Virus Replication
Schmidt et al., American Journal of Transplantation (2014) - PMID: 24726000 - MART-1 Peptide Vaccination Plus IMP321 (LAG-3Ig fusion protein) in Patients Receiving Autologous PBMCs After Lymphodepletion: Results of a Phase I Trial
Romano et al., Journal of Translational Medicine (2014) - PMID: 24726012 - TLR2-Dependent Protection Against Pneumococcal Carriage by Immunization with Lipidated Pneumococcal Proteins
Moffitt et al., Infection and Immunol. (2014) - PMID: 24614661 - An Enzyme-Linked Immunospot Assay for the Detection of Human Respiratory Syncytial Virus F-Specific IFNγ-producing T Cells
Patton et al., Clin Vaccine Immunol. (2014) - PMID: 24574540 - Influence of Frequent Infectious Exposures on General and Varicella-zoster Virus Specific Immune Responses in Pediatricians
Ogunjimi et al., Clin Vaccine Immunol. (2014) - PMID: 24429070 - Deficient EBV-Specific B- and T-Cell Response in Patients with Chronic Fatigue Syndrome
Loebl et al., PLOS ONE (2014) - PMID: 24454857 - HIV Infection in Uncircumcised Men Is Associated With Altered CD8 T-cell Function But Normal CD4 T-cell Numbers in the Foreskin
Prodger et al., The Journal of Infectious Diseases (2014) - PMID: 24277744 - Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins
Bollard et al., J Clin Oncol. (2013) - PMID: 24344220 - Cytomegalovirus Vaccine Strain Towne-Derived Dense Bodies Induce Broad Cellular Immune Responses and Neutralizing Antibodies that Prevent Infection of Fibroblasts and Epithelial Cells
Cayatte et al., J. of Virology (2013) - PMID: 23926341 - Mechanistic Insights Into the Impairment of Memory B Cells and Antibody Production in the Elderly
Aberle et al., AGE (2013) - PMID: 22282053 - Detection of Epstein-Barr Virus-Specific Memory CD4+ T Cells Using a Peptide-Based Cultured Enzyme-Linked Immunospot Assay
Calarota et al., Immunology (2013) - PMID: 23560877 - Nonreplicating Vaccines Can Protect African Green Monkeys from the Memphis 37 Strain of Respiratory Syncytial Virus
Eyles et al., Journal of Infectious Diseases (2013) - PMID: 23596321 - Overnight Resting of PBMC Changes Functional Signatures of Antigen Specific T- Cell Responses: Impact for Immune Monitoring within Clinical Trials
Kutscher et al., PLoS One (2013) - PMID: 24146841 - Inflammatory Activation and Recovering BKV-specific Immunity Correlate with Self-Limited BKV Replication after Renal Transplantation
Schachtner et al., Transplant International (2013) - PMID: 24279642 - Adoptive Immunotherapy with Antigen-Specific T Cells During Extracorporeal Membrane Oxygenation (ECMO) for Adenovirus-Related Respiratory Failure in a Child Given Haploidentical Stem Cell Transplantatio
Di Nardo et al., Pediatric Blood & Cancer (2013) - PMID: 24039155 - Rapid Generation of EBV-Specific Cytotoxic T Lymphocytes Resistant to Calcineurin Inhibitors for Adoptive Immunotherapy
Ricciardelli et al., American Journal of Transplantation (2013) - PMID: 24266973 - The Immunogenicity of Virus-Derived 2A Sequences in Immunocompetent Individuals
Arber et al., Gene Therapy (2013) - PMID: 23698740 - Adoptive T-Cell Transfer and Chemotherapy in the First-Line Treatment of Metastatic and/or Locally Recurrent Nasopharyngeal Carcinoma
Chia et al., Molecular Therapy (2013) - PMID: 24297049 - Combination of Epstein-Barr Virus Nuclear Antigen 1, 3 and Lytic Antigen BZLF1 Peptide Pools Allows Fast and Efficient Stimulation of Epstein-Barr Virus-Specific T Cells for Adoptive Immunotherapy
Wang et al., Cytotherapy (2013) - PMID: 24094498 - A Novel Cytomegalovirus-Induced Regulatory-Type T-Cell Subset Increases in Size During Older Life and Links Virus-Specific Immunity to Vascular Pathology
Terrazzini et al., The Journal of Infectious Disease (2013) - PMID: 24203779 - Putting Polyphosphates to the Test: Evidence Against Platelet-Induced Activation of Factor XII
Faxälv et al., Blood (2013) - PMID: 23896408 - Short-Term In-Vitro Expansion Improves Monitoring and Allows Affordable Generation of Virus-Specific T-Cells against Several Viruses for a Broad Clinical Application
Geyeregger et al., PLOS ONE (2013) - PMID: 23630567 - Adoptive Transfer of Epstein-Barr Virus (EBV) Nuclear Antigen 1–Specific T Cells As Treatment for EBV Reactivation and Lymphoproliferative Disorders After Allogeneic Stem-Cell Transplantation
Icheva et al., JCO (2013) - PMID: 23169501 - Human Papillomavirus Type 16 E6/E7-Specific Cytotoxic T Lymphocytes for Adoptive Immunotherapy of HPV-Associated Malignancies
Ramos et al., Journal of Immunotherapy (2013) - PMID: 23211628 - Cytomegalovirus-Specific CD4 and CD8 T Cell Responses in Infants and Children
Lidehäll et al., Scandinavian Journal of Immunology (2013) - PMID: 23216075 - The Effects of Age and Latent Cytomegalovirus Infection on the Redeployment of CD8+ T Cell Subsets in Response to Acute Exercise in Humans
Spielmann et al., Brain, Behavior, and Immunity (2013) - PMID: 23684819 - The Third Signal Cytokine IL-12 Rescues the Anti-Viral Function of Exhausted HBV-Specific CD8 T Cells
Schurich et al., PLOS Pathogens (2013) - PMID: 23516358 - Antibody Quality and Protection from Lethal Ebola Virus Challenge in Nonhuman Primates Immunized with Rabies Virus Based Bivalent Vaccine
Blaney et al., PLOS Pathogens (2013) - PMID: 23737747 - Donor-Derived CMV-Specific T Cells Reduce The Requirement For CMV-Directed Pharmacotherapy After Allogeneic Stem Cell Transplantation
Blyth et al., Blood. (2013) - PMID: 23435462 - Antigen-Reactive T Cell Enrichment for Direct, High-Resolution Analysis of the Human Naive and Memory Th Cell Repertoire
Bacher et al., J. Immunol. (2013) - PMID: 23479226 - An Adjuvanted Herpes Simplex Virus 2 Subunit Vaccine Elicits a T Cell Response in Mice and Is an Effective Therapeutic Vaccine in Guinea Pigs
Skoberne et al., J. Virol. (2013) - PMID: 23365421 - Distinct Gene-Expression Profiles Associated With the Susceptibility of Pathogen-Specific CD4 T Cells to HIV-1 Infection
Hu et al., Blood. (2013) - PMID: 23258923 - IL-7– and IL-15–Mediated TCR Sensitization Enables T Cell Responses to Self-Antigens
Deshpande et al., J. Immunol. (2013) - PMID: 23325887 - Up-Regulation of a Death Receptor Renders Antiviral T Cells Susceptible to NK Cell–Mediated Deletion
Peppa et al., J. Exp. Med. (2012) - PMID: 23254287 - Reconstitution of Protective Immune Responses against Cytomegalovirus and Varicella Zoster Virus Does Not Require Disease Development in Pediatric Recipients of Umbilical Cord Blood Transplantation
Merindol et al., J. Immunol. (2012) - PMID: 23034171 - Antiviral T Cell Response Triggers Cytomegalovirus Hepatitis in Mice
Livingston-Rosanoff et al., J. Virol. (2012) - PMID: 22993151 - Full-Length HIV-1 Immunogens Induce Greater Magnitude and Comparable Breadth of T Lymphocyte Responses to Conserved HIV-1 Regions Compared with Conserved-Region-Only HIV-1 Immunogens in Rhesus Monkeys
Stephenson et al., J. Virol. (2012) - PMID: 22896617 - Polyclonal Mucosa-Associated Invariant T Cells Have Unique Innate Functions in Bacterial Infection
Chua et al., Infect. Immun. (2012) - PMID: 22778103 - Differential Patterns of Large Tumor Antigen-Specific Immune Responsiveness in Patients with BK Polyomavirus-Positive Prostate Cancer or Benign Prostatic Hyperplasia
Sais et al., J. Virol. (2012) - PMID: 22647697 - Single-Cell Level Response of HIV-Specific and Cytomegalovirus-Specific CD4 T Cells Correlate With Viral Control in Chronic HIV-1 Subtype A Infection
Eller et al., J Acquir Immune Defic Syndr (2012) - PMID: 22580564 - A Novel Th Cell Epitope of Candida albicans Mediates Protection from Fungal Infection
Bär et al., J. Immunol. (2012) - PMID: 22529294 - Three Sensitive Assays Do Not Provide Evidence for Circulating HuD-specific T Cells in the Blood of Patients with Paraneoplastic Neurological Syndromes with Anti-Hu Antibodies
de Jongste et al., Neuro Oncology. (2012) - PMID: 22591661 - Performance of the QuantiFERON-Cytomegalovirus (CMV) Assay for Detection and Estimation of the Magnitude and Functionality of the CMV-Specific Gamma Interferon-Producing CD8+ T-Cell Response in Allogeneic Stem Cell Transplant Recipients
Clari et al., Clin Vaccine Immunol May (2012) - PMID: 22379065 - The Thai Phase III Trial (RV144) Vaccine Regimen Induces T Cell Responses That Preferentially Target Epitopes within the V2 Region of HIV-1 Envelope
de Souza et al., J. Immunol. (2012) - PMID: 22529301 - Preferential Expansion of Human Virus-Specific Multifunctional Central Memory T Cells by Partial Targeting of the IL-2 Receptor Signaling Pathway: The Key Role of CD4+ T Cells
Schmueck et al., J. Immunol. (2012) - PMID: 22516956 - T-Cell Therapy for EBV-Associated Nasopharyngeal Carcinoma: Preparative Lymphodepleting Chemotherapy Does not Improve Clinical Results
Secondino et al., Ann. Onc. (2012) - PMID: 21586688 - A Whole Blood Monokine-Based Reporter Assay Provides a Sensitive and Robust Measurement of the Antigen-Specific T Cell Response
Chakera et al., Journal of Translational Medicine (2011) - PMID: 21871084 - Live and Inactivated Influenza Vaccines Induce Similar Humoral Responses, but Only Live Vaccines Induce Diverse T-Cell Responses in Young Children
Hoft et al., The Journal of Infectious Disease (2011) - PMID: 21846636 - Rebound of Residual Plasma Viremia After Initial Decrease Following Addition of Intravenous Immunoglobulin to Effective Antiretroviral Treatment of HIV
Mellberg et al., AIDS Research and Therapy (2011) - PMID: 21708049 - A Phase II Study Evaluating the Safety and Efficacy of an Adenovirus-LMP1-LMP2 Transduced Dendritic Cell Vaccine in Patients with Advanced Metastatic Nasopharyngeal Carcinoma
Chia et al., Ann. Onc. (2011) - PMID: 21821548 - Polyomavirus BK Large T-Antigen Derived Peptide Elicits a HLA-DR Promiscuous and Polyfunctional CD4+ T-cell Response
Ramaswami et al., Clin. Vaccine Immunol (2011) - PMID: 21367979 - Expansion of T Cells Targeting Multiple Antigens of Cytomegalovirus, Epstein – Barr Virus and Adenovirus to Provide Broad Antiviral Specificity After Stem Cell Transplantation
Hanley et al., Cytotherapy (2011) - PMID: 21539497 - Adoptive Transfer of EBV-Specific T Cells Results in Sustained Clinical Responses in Patients With Locoregional Nasopharyngeal Carcinoma
Louis et al., J Immunother (2010) - PMID: 20948438 - Effective and Long-Term Control of EBV PTLD After Transfer of Peptide-Selected T Cells
Moosmann et al., Blood (2010) - PMID: 20103780 - Accelerated Production of Antigen-Specific T-Cells for Pre-Clinical and Clinical Applications Using Gas-permeable Rapid Expansion Cultureware (G-Rex)
Vera et al., J Immunother. (2010) - PMID: 20445351 - Derivation of Human T Lymphocytes From Cord Blood and Peripheral Blood with Antiviral and Antileukemic Specificity from a Single Culture as Protection Against Infection and Relapse after Stem Cell Transplantation
Micklethwaite et al., Blood (2010) - PMID: 20110422 - Absence of Systemic Immune Response to Adenovectors After Intraocular Administration to Children With Retinoblastoma
Ildefonso et al., Molecular Therapy (2010) - PMID: 20606647 - Nucleofection of DCs to Generate Multivirusspecific T Cells for Prevention or Treatment of Viral Infections in the Immunocompromised Host
Gerdemann et al., Molecular Therapy (2009) - PMID: 19584818 - Cytotoxic T Lymphocyte Therapy with Donor T Cells Prevents and Treats Adenovirus and Epstein-Barr Virus Infections after Haploidentical and Matched Unrelated Stem Cell Transplantation
Leen et al., Blood (2009) - PMID: 19700662 - Tuberculosis Subunit Vaccination Provides Long-Term Protective Immunity Characterized by Multifunctional CD4 Memory T Cells
Lindenstrom et al., J. Immunol (2009) - PMID: 19494330 - Enhancing the In Vivo Expansion of Adoptively Transferred EBV-Specific CTL with Lymphodepleting CD45 Monoclonal Antibodies in NPC Patients
Louis et al., Blood (2009) - PMID: 18971421 - Mesenchymal Stem Cells Exert Differential Effects on Alloantigen and Virus-Specific T-cell Responses
Karlsson et al., Blood (2008) - PMID: 18445691 - Prospective Monitoring of Polyomavirus BK Replication and Impact of Pre-Emptive Intervention in Pediatric Kidney Recipients
Ginevri et al., American Journal of Transplantation (2007) - PMID: 17908275 - Contact-Activated Monocytes: Efficient Antigen Presenting Cells for the Stimulation of Antigen-specific T cells
Leen et al., J Immunother (2007) - PMID: 17198088
Loading...